

Summary of Feed Carcinogenicity Study
of 2-Amino-4-Chlorophenol
in B6D2F1 Mice

September 2008

Japan Bioassay Research Center

Japan Industrial Safety and Health Association

PREFACE

The tests were contracted and supported by the Ministry of Health, Labour and Welfare of Japan. The tests were conducted by Japan Bioassay Research Center (JBRC) and the report was prepared by JBRC and peer reviewed by outside expert pathologist. Complete report was submitted to Ministry of Health, Labour and Welfare of Japan on September 30, 2008.

This English Summary was translated by JBRC from Japanese complete report.

Summary of Feed Carcinogenicity Study of 2-Amino-4-chlorophenol in B6D2F1 MICE

Purpose, materials and methods

2-Amino-4-chlorophenol (ACP, CAS No. 95-85-2) is a crystalline solid with a melting point of 137°C. It is insoluble in water.

The carcinogenicity and chronic toxicity of ACP (greater than 99.1% pure) were examined by feeding groups of B6D2F1/Crlj mice ACP-containing diets for 2 years (104 weeks). Each group of test animals consisted of either 50 male or 50 female mice. The dietary concentration of ACP was 0, 512, 1280, or 3200 ppm (w/w). Both sexes were exposed to each concentration of ACP. The highest dose level was chosen so as not to exceed the maximum tolerated dose (MTD), based on both growth rate and toxicity in a previous 13-week toxicity study. The identity of the ACP used in these experiments was confirmed by both infrared spectrometry and mass spectrometry, and it was analyzed by gas chromatography before and after its use to affirm its stability. To ensure that the concentration of ACP in the diet remained constant, the concentration of APC in the diet was determined by high performance liquid chromatography at the time of preparation and on the 4th day after preparation; ACP-containing food was stored at room temperature. The animals were observed daily for clinical signs and mortality. Body weight and food consumption were measured once a week for the first 14 weeks and every 4 weeks thereafter. All animals, including those found dead or in a moribund state as well as those surviving to the end of the 2-year exposure period, underwent complete necropsy. Urinalysis was performed near the end of the administration period. For hematology and blood biochemistry at the terminal necropsy, surviving animals were fasted overnight and bled under deep ether anesthesia. Organs and tissues were removed, weighed and examined for macroscopic lesions at necropsy. The organs and tissues were then fixed and embedded in paraffin. Five µm thick tissue sections were prepared and stained with hematoxylin and eosin and examined microscopically. Incidences of neoplastic lesions were statistically analyzed by Fisher's exact test. Any positive dose-response trends of ACP induction of neoplastic lesions were analyzed by Peto's test. Incidences of non-neoplastic lesions and urinalysis were analyzed by the Chi-square test. Changes in body weight, food consumption, hematological and blood biochemical parameters, and organ weights were analyzed by Dunnett's test. The present studies were conducted in accordance with the Organisation for Economic Co-operation and Development (OECD) Good Laboratory Practice and with reference to the OECD Guideline for Testing of Chemicals 451 "Carcinogenicity Studies".

Results

There was no significant difference in survival rate, body weight or food consumption between any ACP-fed group of either sex and their respective controls.

The incidence of squamous cell papillomas in the forestomach was increased in the 3200 ppm-fed male group compared to their control group. Also, the incidences of squamous cell papillomas in the forestomach in all ACP-fed male groups were higher than the historical control data of the Japan Bioassay Research Center (JBRC). Therefore, the increased incidences of squamous cell papillomas in the forestomach in males is related to ACP administration. A slight increase in the incidence of squamous cell papillomas in the forestomach was also observed in the ACP-fed females, but those incidences were within the range of historical JBRC control data.

Conclusions

In mice, there was some evidence of carcinogenic activity of 2-amino-4-chlorophenol in males, based on an increased incidences of squamous cell papillomas in the forestomach. There was no evidence of carcinogenic activity of 2-amino-4-chlorophenol in females.

SELECTED TABLES

TABLE C 1 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS:
MALE

TABLE C 2 BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS:
FEMALE

TABLE C 3 BODY WEIGHT CHANGES: MALE

TABLE C 4 BODY WEIGHT CHANGES: FEMALE

TABLE D 1 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: MALE

TABLE D 2 FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL
NUMBERS: FEMALE

TABLE D 3 FOOD CONSUMPTION CHANGES: MALE

TABLE D 4 FOOD CONSUMPTION CHANGES: FEMALE

TABLE E 1 CHEMICAL INTAKE CHANGES: MALE

TABLE E 2 CHEMICAL INTAKE CHANGES: FEMALE

TABLE F 1 HEMATOLOGY: MALE

TABLE F 2 HEMATOLOGY: FEMALE

TABLE G 1 BIOCHEMISTRY: MALE

TABLE G 2 BIOCHEMISTRY: FEMALE

TABLE H 1 URINALYSIS: MALE

TABLE H 2 URINALYSIS: FEMALE

TABLE J 1 ORGAN WEIGHT, ABSOLUTE: MALE

TABLE J 2 ORGAN WEIGHT, ABSOLUTE: FEMALE

TABLE K 1 ORGAN WEIGHT, RELATIVE: MALE

TABLE K 2 ORGAN WEIGHT, RELATIVE: FEMALE

TABLE L 1 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS:
MALE: ALL ANIMALS

TABLE L 4 HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC LESIONS:
FEMALE: ALL ANIMALS

TABLE O 1 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL
ANALYSIS: MALE

TABLE O 2 NEOPLASTIC LESIONS-INCIDENCE AND STATISTICAL
ANALYSIS: FEMALE

TABLE Q 1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: B6D2F1/Crlj
MALE MICE

TABLE Q 2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER: B6D2F1/Crlj
FEMALE MICE

TABLE R CAUSE OF DEATH OF MICE IN THE 2-YEAR FEED STUDY OF
2-AMINO-4-CHLOROPHENOL

TABLE C 1

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS: MALE

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrLi[Cxj:BDP1]
UNIT : g
REPORT TYPE : A1 104
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

PAGE : 1

| Week Day on Study | Control | | | 512 ppm | | | 1280 ppm | | | 3200 ppm | | |
|----------------------|-----------|---------------------------|-----------|-----------------------|-------------------|-----------|-----------------------|-------------------|-----------|-----------------------|-------------------|--|
| | Av. Wt. | No. of Surviv. <50> | Av. Wt. | % of cont. <50> | No. of Surviv. | Av. Wt. | % of cont. <50> | No. of Surviv. | Av. Wt. | % of cont. <50> | No. of Surviv. | |
| 0-0 | 21.0 (50) | 50/50 | 24.0 (50) | 100 | 50/50 | 24.0 (50) | 100 | 50/50 | 24.0 (50) | 100 | 50/50 | |
| 1-7 | 25.4 (50) | 50/50 | 25.1 (50) | 99 | 50/50 | 25.1 (50) | 99 | 50/50 | 24.7 (50) | 97 | 50/50 | |
| 2-7 | 26.4 (50) | 50/50 | 26.1 (50) | 99 | 50/50 | 25.8 (50) | 98 | 50/50 | 25.8 (50) | 98 | 50/50 | |
| 3-7 | 27.3 (50) | 50/50 | 27.0 (50) | 99 | 50/50 | 27.0 (50) | 99 | 50/50 | 26.6 (50) | 97 | 50/50 | |
| 4-7 | 28.2 (50) | 50/50 | 27.7 (50) | 98 | 50/50 | 27.9 (50) | 99 | 50/50 | 27.3 (50) | 97 | 50/50 | |
| 5-7 | 29.1 (50) | 50/50 | 28.7 (50) | 99 | 50/50 | 28.8 (50) | 99 | 50/50 | 28.4 (50) | 98 | 50/50 | |
| 6-7 | 29.7 (50) | 50/50 | 29.4 (50) | 99 | 50/50 | 29.5 (50) | 99 | 50/50 | 29.1 (50) | 98 | 50/50 | |
| 7-7 | 30.6 (50) | 50/50 | 30.0 (50) | 98 | 50/50 | 30.2 (50) | 99 | 50/50 | 29.8 (50) | 97 | 50/50 | |
| 8-7 | 31.2 (50) | 50/50 | 30.9 (50) | 99 | 50/50 | 30.7 (50) | 98 | 50/50 | 30.2 (50) | 97 | 50/50 | |
| 9-7 | 31.9 (50) | 50/50 | 31.6 (50) | 99 | 50/50 | 31.5 (50) | 99 | 50/50 | 31.1 (49) | 97 | 49/50 | |
| 10-7 | 32.3 (50) | 50/50 | 32.0 (50) | 99 | 50/50 | 32.1 (50) | 99 | 50/50 | 32.0 (49) | 99 | 49/50 | |
| 11-7 | 33.0 (50) | 50/50 | 32.0 (50) | 97 | 50/50 | 32.4 (50) | 98 | 50/50 | 32.1 (49) | 97 | 49/50 | |
| 12-7 | 34.3 (50) | 50/50 | 33.4 (50) | 97 | 50/50 | 33.6 (50) | 98 | 50/50 | 33.4 (49) | 97 | 49/50 | |
| 13-7 | 35.0 (50) | 50/50 | 34.6 (50) | 99 | 50/50 | 34.5 (50) | 99 | 50/50 | 34.1 (49) | 97 | 49/50 | |
| 14-7 | 35.4 (50) | 50/50 | 35.2 (50) | 99 | 50/50 | 35.1 (50) | 99 | 50/50 | 34.8 (49) | 98 | 49/50 | |
| 18-7 | 37.8 (50) | 50/50 | 37.9 (50) | 100 | 50/50 | 37.7 (50) | 100 | 50/50 | 37.6 (49) | 99 | 49/50 | |
| 22-7 | 40.0 (50) | 50/50 | 39.4 (50) | 99 | 50/50 | 39.4 (50) | 99 | 50/50 | 39.1 (49) | 98 | 49/50 | |
| 26-7 | 42.9 (50) | 50/50 | 42.5 (49) | 99 | 49/50 | 42.0 (50) | 98 | 50/50 | 41.4 (49) | 97 | 49/50 | |
| 30-7 | 44.5 (50) | 50/50 | 44.1 (49) | 99 | 49/50 | 43.7 (50) | 98 | 50/50 | 43.0 (49) | 97 | 49/50 | |
| 34-7 | 46.3 (49) | 49/50 | 46.1 (49) | 100 | 49/50 | 44.8 (50) | 97 | 50/50 | 44.2 (49) | 95 | 49/50 | |
| 38-7 | 47.5 (49) | 49/50 | 47.5 (49) | 100 | 49/50 | 46.2 (50) | 97 | 50/50 | 46.2 (49) | 97 | 49/50 | |
| 42-7 | 49.2 (49) | 49/50 | 48.4 (49) | 98 | 49/50 | 47.7 (50) | 97 | 50/50 | 47.6 (48) | 97 | 48/50 | |
| 46-7 | 50.7 (48) | 48/50 | 49.9 (49) | 98 | 49/50 | 49.3 (50) | 97 | 50/50 | 48.9 (48) | 96 | 48/50 | |
| 50-7 | 51.4 (48) | 48/50 | 49.5 (49) | 96 | 49/50 | 49.3 (50) | 96 | 50/50 | 49.3 (48) | 96 | 48/50 | |
| 54-7 | 52.1 (48) | 48/50 | 51.2 (49) | 98 | 49/50 | 50.6 (50) | 97 | 50/50 | 50.9 (47) | 98 | 47/50 | |
| 58-7 | 52.1 (47) | 47/50 | 50.9 (49) | 98 | 49/50 | 51.1 (49) | 98 | 49/50 | 50.6 (47) | 97 | 47/50 | |
| 62-7 | 52.8 (47) | 47/50 | 51.6 (49) | 98 | 49/50 | 52.1 (48) | 99 | 48/50 | 51.2 (47) | 97 | 47/50 | |
| 66-7 | 53.3 (45) | 45/50 | 52.1 (48) | 98 | 48/50 | 52.2 (47) | 98 | 47/50 | 51.7 (47) | 97 | 47/50 | |
| 70-7 | 53.4 (43) | 43/50 | 52.9 (48) | 99 | 48/50 | 52.6 (46) | 99 | 46/50 | 52.4 (47) | 98 | 47/50 | |
| 74-7 | 54.4 (43) | 43/50 | 53.8 (46) | 99 | 46/50 | 52.9 (45) | 97 | 45/50 | 53.1 (47) | 98 | 47/50 | |
| 78-7 | 55.0 (43) | 43/50 | 54.4 (45) | 99 | 45/50 | 52.9 (45) | 96 | 45/50 | 53.4 (47) | 97 | 47/50 | |
| 82-7 | 53.8 (43) | 43/50 | 53.6 (45) | 100 | 45/50 | 52.8 (44) | 98 | 44/50 | 53.2 (45) | 99 | 45/50 | |
| 86-7 | 53.3 (40) | 40/50 | 53.4 (45) | 100 | 45/50 | 52.5 (43) | 98 | 43/50 | 53.0 (45) | 99 | 45/50 | |
| 90-7 | 54.4 (37) | 37/50 | 55.7 (43) | 102 | 43/50 | 54.0 (41) | 99 | 41/50 | 53.9 (42) | 99 | 42/50 | |
| 94-7 | 51.8 (37) | 37/50 | 56.4 (40) | 109 | 40/50 | 51.9 (40) | 100 | 40/50 | 52.5 (40) | 101 | 40/50 | |
| 98-7 | 51.5 (34) | 34/50 | 54.9 (38) | 107 | 38/50 | 50.4 (38) | 98 | 38/50 | 52.5 (38) | 102 | 38/50 | |
| 102-7 | 50.5 (33) | 33/50 | 55.1 (35) | 109 | 35/50 | 49.4 (38) | 98 | 35/50 | 52.6 (36) | 104 | 36/50 | |
| 104-7 | 48.8 (33) | 33/50 | 53.0 (34) | 109 | 34/50 | 49.3 (36) | 101 | 36/50 | 51.7 (35) | 106 | 35/50 | |

< >:No. of effective animals, ():No. of measured animals

Av. Wt.: g

(B10040)

BALS 4

TABLE C 2

BODY WEIGHT CHANGES AND
SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0580
ANIMAL : MOUSE B612H1/Cr1j[Crj:EDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

| Week-Day on Study | Control | | | 512 ppm | | | 1280 ppm | | | 3200 ppm | | |
|----------------------|-----------|---------------------------|-----------|-----------------------|-------------------|-----------|-----------------------|-------------------|-----------|-----------------------|-------------------|--|
| | Av. Wt. | No. of Surviv. <50> | Av. Wt. | % of cont. <50> | No. of Surviv. | Av. Wt. | % of cont. <50> | No. of Surviv. | Av. Wt. | % of cont. <50> | No. of Surviv. | |
| 0-0 | 19.2 (50) | 50/50 | 19.2 (50) | 100 | 50/50 | 19.2 (50) | 100 | 50/50 | 19.2 (50) | 100 | 50/50 | |
| 1-7 | 20.1 (50) | 50/50 | 20.1 (50) | 100 | 50/50 | 19.8 (50) | 99 | 50/50 | 19.7 (50) | 98 | 50/50 | |
| 2-7 | 20.3 (50) | 50/50 | 20.5 (50) | 101 | 50/50 | 20.2 (50) | 100 | 50/50 | 20.2 (50) | 100 | 50/50 | |
| 3-7 | 20.9 (50) | 50/50 | 20.9 (50) | 100 | 50/50 | 20.9 (50) | 100 | 50/50 | 20.6 (50) | 99 | 50/50 | |
| 4-7 | 21.3 (50) | 50/50 | 21.3 (50) | 100 | 50/50 | 21.2 (50) | 100 | 50/50 | 21.2 (50) | 100 | 50/50 | |
| 5-7 | 22.1 (50) | 50/50 | 22.1 (50) | 100 | 50/50 | 22.0 (50) | 100 | 50/50 | 21.9 (50) | 99 | 50/50 | |
| 6-7 | 22.5 (50) | 50/50 | 22.3 (50) | 99 | 50/50 | 22.4 (50) | 100 | 50/50 | 22.4 (50) | 100 | 50/50 | |
| 7-7 | 22.7 (50) | 50/50 | 23.0 (50) | 101 | 50/50 | 22.8 (50) | 100 | 50/50 | 22.8 (50) | 100 | 50/50 | |
| 8-7 | 23.6 (50) | 50/50 | 23.7 (50) | 100 | 50/50 | 23.2 (50) | 98 | 50/50 | 23.6 (50) | 100 | 50/50 | |
| 9-7 | 24.0 (50) | 50/50 | 24.2 (50) | 101 | 50/50 | 23.6 (50) | 98 | 50/50 | 23.7 (50) | 99 | 50/50 | |
| 10-7 | 24.2 (50) | 50/50 | 24.7 (50) | 102 | 50/50 | 24.0 (50) | 99 | 50/50 | 24.1 (50) | 100 | 50/50 | |
| 11-7 | 24.7 (50) | 50/50 | 24.8 (50) | 100 | 50/50 | 24.0 (50) | 97 | 50/50 | 24.2 (50) | 98 | 50/50 | |
| 12-7 | 24.8 (50) | 50/50 | 25.1 (50) | 101 | 50/50 | 24.6 (50) | 99 | 50/50 | 24.7 (50) | 100 | 50/50 | |
| 13-7 | 25.8 (50) | 50/50 | 25.8 (50) | 100 | 50/50 | 25.1 (50) | 97 | 50/50 | 25.3 (50) | 98 | 50/50 | |
| 14-7 | 26.3 (50) | 50/50 | 26.2 (50) | 100 | 50/50 | 25.6 (50) | 97 | 50/50 | 25.8 (50) | 98 | 50/50 | |
| 18-7 | 27.5 (50) | 50/50 | 27.9 (50) | 101 | 50/50 | 27.0 (50) | 98 | 50/50 | 27.2 (50) | 99 | 50/50 | |
| 22-7 | 29.0 (50) | 50/50 | 29.2 (50) | 101 | 50/50 | 28.7 (50) | 99 | 50/50 | 28.9 (49) | 100 | 49/50 | |
| 26-7 | 31.2 (50) | 50/50 | 31.4 (50) | 101 | 50/50 | 30.5 (50) | 98 | 50/50 | 30.3 (49) | 97 | 49/50 | |
| 30-7 | 32.0 (50) | 50/50 | 32.7 (50) | 102 | 50/50 | 31.7 (50) | 99 | 50/50 | 31.4 (49) | 98 | 49/50 | |
| 34-7 | 33.4 (50) | 50/50 | 33.9 (50) | 101 | 50/50 | 32.6 (50) | 98 | 50/50 | 32.4 (49) | 97 | 49/50 | |
| 38-7 | 34.7 (50) | 50/50 | 35.3 (50) | 102 | 50/50 | 34.4 (50) | 99 | 50/50 | 34.6 (49) | 100 | 49/50 | |
| 42-7 | 35.9 (50) | 50/50 | 36.8 (50) | 103 | 50/50 | 35.4 (50) | 99 | 50/50 | 36.3 (48) | 101 | 48/50 | |
| 46-7 | 37.0 (50) | 50/50 | 37.7 (50) | 102 | 50/50 | 36.3 (50) | 98 | 50/50 | 37.6 (48) | 102 | 48/50 | |
| 50-7 | 37.4 (50) | 50/50 | 38.8 (50) | 104 | 50/50 | 36.9 (50) | 99 | 50/50 | 38.1 (48) | 102 | 48/50 | |
| 54-7 | 39.0 (50) | 50/50 | 40.1 (50) | 103 | 50/50 | 38.6 (50) | 99 | 50/50 | 39.5 (48) | 101 | 48/50 | |
| 58-7 | 38.8 (50) | 50/50 | 39.8 (49) | 103 | 49/50 | 38.6 (50) | 99 | 50/50 | 39.2 (48) | 101 | 48/50 | |
| 62-7 | 39.1 (50) | 50/50 | 40.0 (48) | 102 | 48/50 | 38.9 (49) | 99 | 49/50 | 39.8 (48) | 102 | 48/50 | |
| 66-7 | 39.7 (49) | 49/50 | 41.1 (47) | 104 | 47/50 | 39.5 (49) | 99 | 49/50 | 40.6 (48) | 102 | 48/50 | |
| 70-7 | 39.5 (49) | 49/50 | 41.3 (47) | 105 | 47/50 | 39.7 (49) | 101 | 49/50 | 40.6 (47) | 103 | 47/50 | |
| 74-7 | 40.0 (49) | 49/50 | 41.7 (47) | 104 | 47/50 | 40.2 (48) | 101 | 48/50 | 40.6 (47) | 102 | 47/50 | |
| 78-7 | 41.3 (48) | 48/50 | 42.3 (46) | 102 | 46/50 | 40.6 (47) | 98 | 47/50 | 41.2 (46) | 100 | 46/50 | |
| 82-7 | 40.1 (48) | 48/50 | 42.5 (44) | 106 | 44/50 | 39.9 (47) | 100 | 47/50 | 40.8 (44) | 102 | 44/50 | |
| 86-7 | 39.8 (47) | 47/50 | 42.8 (43) | 108 | 43/50 | 40.8 (44) | 103 | 44/50 | 40.7 (41) | 102 | 41/50 | |
| 90-7 | 39.9 (45) | 45/50 | 43.3 (41) | 109 | 41/50 | 41.3 (40) | 104 | 40/50 | 41.0 (38) | 103 | 38/50 | |
| 94-7 | 39.0 (41) | 41/50 | 41.7 (39) | 107 | 39/50 | 41.4 (36) | 106 | 36/50 | 40.3 (36) | 103 | 36/50 | |
| 98-7 | 40.8 (36) | 36/50 | 41.6 (34) | 102 | 34/50 | 41.0 (33) | 100 | 33/50 | 40.1 (34) | 98 | 34/50 | |
| 102-7 | 40.5 (34) | 34/50 | 41.3 (29) | 102 | 29/50 | 41.5 (30) | 102 | 30/50 | 38.8 (30) | 96 | 30/50 | |
| 104-7 | 39.6 (34) | 34/50 | 39.1 (28) | 99 | 28/50 | 40.6 (28) | 103 | 28/50 | 38.1 (30) | 96 | 30/50 | |

< :>:No. of effective animals, ():No. of measured animals Av. Wt. : g

(B10040)

TABLE C 3

BODY WEIGHT CHANGES: MALE

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 1

| Group Name | Administration week-day | | | | | | | (SUMMARY) |
|------------|-------------------------|-------------|------------|-----------|-------------|-----------|-----------|-----------|
| | 0-0 | 1-7 | 2-7 | 3-7 | 4-7 | 5-7 | 6-7 | |
| Control | 24.0± 0.8 | 25.4± 1.2 | 26.4± 1.3 | 27.3± 1.4 | 28.2± 1.5 | 29.1± 1.6 | 29.7± 1.6 | |
| 512 ppm | 24.0± 0.8 | 25.1± 1.0 | 26.1± 0.9 | 27.0± 1.1 | 27.7± 1.3 | 28.7± 1.4 | 29.4± 1.4 | |
| 1280 ppm | 24.0± 0.8 | 25.1± 1.0 | 25.8± 1.3* | 27.0± 1.4 | 27.9± 1.5 | 28.8± 1.8 | 29.5± 1.8 | |
| 3200 ppm | 24.0± 0.8 | 24.7± 1.2** | 25.8± 1.2* | 26.6± 1.6 | 27.3± 1.9** | 28.4± 1.7 | 29.1± 2.0 | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr1J[Crj:BDNF1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 2

| Group Name | Administration week-day | | | | | | |
|------------|-------------------------|-----------|-----------|-----------|-----------|-----------|-----------|
| | 7-7 | 8-7 | 9-7 | 10-7 | 11-7 | 12-7 | 13-7 |
| Control | 30.6± 1.7 | 31.2± 1.7 | 31.9± 2.0 | 32.3± 2.3 | 33.0± 2.4 | 34.3± 2.3 | 35.0± 2.6 |
| 512 ppm | 30.0± 1.7 | 30.9± 1.7 | 31.6± 1.8 | 32.0± 2.1 | 32.0± 2.1 | 33.4± 1.9 | 34.6± 2.0 |
| 1280 ppm | 30.2± 1.9 | 30.7± 2.1 | 31.5± 2.2 | 32.1± 2.2 | 32.4± 2.3 | 33.6± 2.6 | 34.5± 2.8 |
| 3200 ppm | 29.8± 2.1 | 30.2± 2.4 | 31.1± 1.9 | 32.0± 2.1 | 32.1± 2.1 | 33.4± 2.3 | 34.1± 2.4 |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6DZF1/CrJ[Crj:BDF1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 3

| Group Name | Administration week-day | | | | | | | BODY WEIGHT CHANGES ALL ANIMALS | | (SUMMARY) | |
|------------|-------------------------|-----------|-----------|-----------|-----------|------------|-----------|------------------------------------|--|-----------|--|
| | 14-7 | 18-7 | 22-7 | 26-7 | 30-7 | 34-7 | 38-7 | | | | |
| Control | 35.4± 2.7 | 37.8± 3.8 | 40.0± 4.3 | 42.9± 4.9 | 44.5± 4.9 | 46.3± 4.5 | 47.5± 4.5 | | | | |
| 512 ppm | 35.2± 2.2 | 37.9± 2.5 | 39.4± 3.9 | 42.5± 3.2 | 44.1± 3.3 | 46.1± 3.4 | 47.5± 3.5 | | | | |
| 1280 ppm | 35.1± 2.8 | 37.7± 3.4 | 39.4± 4.0 | 42.0± 4.1 | 43.7± 4.3 | 44.8± 4.2 | 46.2± 4.2 | | | | |
| 3200 ppm | 34.8± 2.4 | 37.6± 2.8 | 39.1± 3.3 | 41.4± 4.1 | 43.0± 4.0 | 44.2± 4.3* | 46.2± 4.5 | | | | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260)

BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : MALE

PAGE : 4

| Group Name | Administration week day | | | | | | BODY WEIGHT CHANGES ALL ANIMALS | (SUMMARY) |
|------------|-------------------------|-----------|------------|-----------|-----------|-----------|------------------------------------|-----------|
| | 42-7 | 46-7 | 50-7 | 54-7 | 58-7 | 62-7 | 66-7 | |
| Control | 49.2± 4.0 | 50.7± 3.8 | 51.4± 3.3 | 52.1± 3.1 | 52.1± 3.9 | 52.8± 4.1 | 53.3± 4.0 | |
| 512 ppm | 48.4± 3.5 | 49.9± 3.2 | 49.5± 3.7* | 51.2± 3.3 | 50.9± 4.0 | 51.6± 4.4 | 52.1± 5.6 | |
| 1280 ppm | 47.7± 3.9 | 49.3± 3.7 | 49.3± 4.3* | 50.6± 4.5 | 51.1± 4.3 | 52.1± 4.4 | 52.2± 4.5 | |
| 3200 ppm | 47.6± 3.9 | 48.9± 4.1 | 49.3± 3.9* | 50.9± 3.8 | 50.6± 4.3 | 51.2± 5.0 | 51.7± 4.6 | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BAIS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr1J[Crj:BDP1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : MALE

PAGE : 5

| Group Name | Administration week-day | | | | | | |
|------------|-------------------------|------------|------------|------------|------------|------------|-------------|
| | 70-7 | 74-7 | 78-7 | 82-7 | 86-7 | 90-7 | 94-7 |
| Control | 53.4 ± 3.8 | 54.4 ± 4.0 | 55.0 ± 4.6 | 53.8 ± 5.9 | 53.3 ± 5.9 | 54.4 ± 6.2 | 51.8 ± 7.0 |
| 512 ppm | 52.9 ± 5.9 | 53.8 ± 6.2 | 54.4 ± 6.6 | 53.6 ± 6.7 | 53.4 ± 8.4 | 55.7 ± 6.7 | 56.4 ± 5.1* |
| 1280 ppm | 52.6 ± 4.7 | 52.9 ± 5.2 | 52.9 ± 6.1 | 52.8 ± 6.1 | 52.5 ± 7.7 | 54.0 ± 6.9 | 51.9 ± 8.1 |
| 3200 ppm | 52.4 ± 5.3 | 53.1 ± 5.3 | 53.4 ± 6.8 | 53.2 ± 4.8 | 53.0 ± 6.0 | 53.9 ± 6.4 | 52.5 ± 6.2 |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HUN260)

BAYS 4

| Group Name | Administration week-day | | 102-7 | | 104-7 | |
|------------|-------------------------|--|------------|--|-----------|--|
| | 98-7 | | | | | |
| Control | 51.5± 7.5 | | 50.5± 7.9 | | 48.8± 8.5 | |
| 512 ppm | 54.9± 6.1 | | 55.1± 6.5* | | 53.0± 6.9 | |
| 1280 ppm | 50.4± 7.9 | | 49.4± 9.7 | | 49.3± 8.4 | |
| 3200 ppm | 52.5± 6.3 | | 52.6± 7.3 | | 51.7± 7.2 | |

Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01

Test of Dunnett

(HAN260)

BATS 4

TABLE C 4

BODY WEIGHT CHANGES: FEMALE

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDF1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

PAGE : 7

| Group Name | Administration week-day | | | | | | BODY WEIGHT CHANGES ALL ANIMALS | (SUMMARY) |
|------------|-------------------------|-----------|-----------|-----------|-----------|-----------|------------------------------------|-----------|
| | 0-0 | 1-7 | 2-7 | 3-7 | 4-7 | 5-7 | | |
| Control | 19.2± 0.8 | 20.1± 1.0 | 20.3± 1.2 | 20.9± 1.2 | 21.3± 1.2 | 22.1± 1.3 | 22.5± 1.3 | |
| 512 ppm | 19.2± 0.8 | 20.1± 1.0 | 20.5± 1.0 | 20.9± 1.0 | 21.3± 1.1 | 22.1± 1.2 | 22.3± 1.3 | |
| 1280 ppm | 19.2± 0.8 | 19.8± 1.0 | 20.2± 1.2 | 20.9± 1.4 | 21.2± 1.4 | 22.0± 1.4 | 22.4± 1.4 | |
| 3200 ppm | 19.2± 0.8 | 19.7± 1.1 | 20.2± 1.1 | 20.6± 1.1 | 21.2± 1.3 | 21.9± 1.3 | 22.4± 1.5 | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ1J[Crlj:BDF1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

PAGE : 8

| Group Name | Administration week-day | | | | | BODY WEIGHT CHANGES | | | (SUMMARY) | | |
|------------|-------------------------|-----------|-----------|-----------|-----------|---------------------|-----------|-------------|-----------|--|--|
| | 7-7 | 8-7 | 9-7 | 10-7 | 11-7 | 12-7 | 13-7 | ALL ANIMALS | | | |
| Control | 22.7± 1.2 | 23.6± 1.5 | 24.0± 1.7 | 24.2± 1.9 | 24.7± 1.9 | 24.8± 2.1 | 25.8± 2.3 | | | | |
| 512 ppm | 23.0± 1.5 | 23.7± 1.5 | 24.2± 1.6 | 24.7± 1.9 | 24.8± 2.2 | 25.1± 2.3 | 25.8± 2.2 | | | | |
| 1280 ppm | 22.8± 1.7 | 23.2± 1.6 | 23.6± 1.9 | 24.0± 1.8 | 24.0± 2.0 | 24.6± 2.1 | 25.1± 2.2 | | | | |
| 3200 ppm | 22.8± 1.5 | 23.6± 1.5 | 23.7± 1.5 | 24.1± 1.8 | 24.2± 1.9 | 24.7± 1.7 | 25.3± 1.9 | | | | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
 UNIT : g
 REPORT TYPE : A1 104
 SEX : FEMALE

PAGE : 9

| Group Name | Administration week day | | | | | | | BODY WEIGHT CHANGES ALL ANIMALS | | (SUMMARY) | |
|------------|-------------------------|-----------|-----------|-----------|-----------|-----------|-----------|------------------------------------|--|-----------|--|
| | 14-7 | 18-7 | 22-7 | 26-7 | 30-7 | 34-7 | 38-7 | | | | |
| Control | 26.3± 2.4 | 27.5± 2.9 | 29.0± 3.4 | 31.2± 3.6 | 32.0± 4.1 | 33.4± 4.4 | 34.7± 4.3 | | | | |
| 512 ppm | 26.2± 2.3 | 27.9± 2.8 | 29.2± 3.0 | 31.4± 3.9 | 32.7± 3.9 | 33.9± 4.3 | 35.3± 4.4 | | | | |
| 1280 ppm | 25.6± 2.3 | 27.0± 2.9 | 28.7± 3.5 | 30.5± 3.8 | 31.7± 4.3 | 32.6± 4.3 | 34.4± 4.8 | | | | |
| 3200 ppm | 25.8± 2.3 | 27.2± 2.9 | 28.9± 3.6 | 30.3± 3.6 | 31.4± 3.8 | 32.4± 4.0 | 34.6± 4.8 | | | | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BAIS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr-L1[Crj:BDFl]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 10

| Group Name | Administration week day | | | | | BODY WEIGHT CHANGES (SUMMARY) | | |
|------------|-------------------------|-----------|-----------|-----------|-----------|-------------------------------|-----------|--|
| | 42-7 | 46-7 | 50-7 | 54-7 | 58-7 | 62-7 | 66-7 | |
| Control | 35.9± 4.6 | 37.0± 5.0 | 37.4± 5.4 | 39.0± 5.5 | 38.8± 5.6 | 39.1± 5.6 | 39.7± 5.2 | |
| 512 ppm | 36.8± 4.4 | 37.7± 4.9 | 38.8± 5.1 | 40.1± 5.1 | 39.8± 5.5 | 40.0± 5.7 | 41.1± 5.7 | |
| 1280 ppm | 35.4± 4.8 | 36.3± 5.0 | 36.9± 4.8 | 38.6± 5.0 | 38.6± 5.4 | 38.9± 5.6 | 39.5± 5.4 | |
| 3200 ppm | 36.3± 3.9 | 37.6± 4.1 | 38.1± 4.2 | 39.5± 4.1 | 39.2± 4.5 | 39.8± 4.2 | 40.6± 4.2 | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HAN260) BAIS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6DZF1/CrJ[Crj:BDP1]
 UNIT : g
 REPORT TYPE : AI 104
 SEX : FEMALE

PAGE : 11

| Group Name | Administration week day | | | | | BODY WEIGHT CHANGES (SUMMARY) | | | |
|------------|-------------------------|-----------|-----------|-----------|-----------|-------------------------------|-----------|--|--|
| | 70-7 | 74-7 | 78-7 | 82-7 | 86-7 | 90-7 | 94-7 | | |
| Control | 39.5± 5.7 | 40.0± 6.5 | 41.3± 6.1 | 40.1± 6.6 | 39.8± 6.2 | 39.9± 7.3 | 39.0± 7.6 | | |
| 512 ppm | 41.3± 6.0 | 41.7± 5.9 | 42.3± 6.1 | 42.5± 6.0 | 42.8± 5.8 | 43.3± 5.8 | 41.7± 6.4 | | |
| 1250 ppm | 39.7± 5.5 | 40.2± 5.2 | 40.6± 5.8 | 39.9± 6.0 | 40.8± 5.3 | 41.3± 6.0 | 41.4± 5.4 | | |
| 3200 ppm | 40.6± 4.1 | 40.6± 4.3 | 41.2± 4.7 | 40.8± 4.8 | 40.7± 5.1 | 41.0± 5.3 | 40.3± 5.6 | | |

| | | | | | |
|----------------------------|---------------|----|---------------|-----------------|--------|
| Significant difference : * | $P \leq 0.05$ | ** | $P \leq 0.01$ | Test of Dunnett | |
| (HAN260) | | | | | BATS 4 |

PAGE : 12

Signi
(HAN260)

TABLE D 1

FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: MALE

| Week-Day on Study | Control | | | 512 ppm | | | 1280 ppm | | | 3200 ppm | | |
|----------------------|----------|---------------------------|----------|-----------------------|-------------------|----------|-----------------------|-------------------|----------|-----------------------|-------------------|-----------------------|
| | Av. FC. | No. of Surviv. <50> | Av. FC. | % of cont. <50> | No. of Surviv. | Av. FC. | % of cont. <50> | No. of Surviv. | Av. FC. | % of cont. <50> | No. of Surviv. | % of cont. <50> |
| 1-7 | 4.2 (50) | 50/50 | 4.1 (50) | 98 | 50/50 | 4.0 (50) | 95 | 50/50 | 4.0 (50) | 95 | 50/50 | 50/50 |
| 2-7 | 3.8 (50) | 50/50 | 4.0 (50) | 105 | 50/50 | 3.8 (50) | 100 | 50/50 | 4.0 (50) | 105 | 50/50 | 50/50 |
| 3-7 | 3.9 (50) | 50/50 | 3.9 (50) | 100 | 50/50 | 4.0 (50) | 103 | 50/50 | 4.1 (50) | 105 | 50/50 | 50/50 |
| 4-7 | 4.0 (50) | 50/50 | 3.9 (50) | 98 | 50/50 | 4.0 (50) | 100 | 50/50 | 3.9 (50) | 98 | 50/50 | 50/50 |
| 5-7 | 4.0 (50) | 50/50 | 3.9 (50) | 98 | 50/50 | 4.0 (50) | 100 | 50/50 | 4.1 (50) | 103 | 50/50 | 50/50 |
| 6-7 | 3.9 (50) | 50/50 | 4.0 (50) | 103 | 50/50 | 3.9 (49) | 100 | 50/50 | 4.1 (50) | 105 | 50/50 | 50/50 |
| 7-7 | 4.0 (50) | 50/50 | 4.0 (50) | 100 | 50/50 | 4.0 (50) | 100 | 50/50 | 4.1 (50) | 103 | 50/50 | 50/50 |
| 8-7 | 4.0 (50) | 50/50 | 4.0 (50) | 100 | 50/50 | 3.9 (50) | 98 | 50/50 | 3.9 (50) | 98 | 50/50 | 50/50 |
| 9-7 | 4.0 (50) | 50/50 | 4.1 (50) | 103 | 50/50 | 4.2 (50) | 105 | 50/50 | 4.1 (49) | 103 | 49/50 | 49/50 |
| 10-7 | 4.0 (50) | 50/50 | 4.0 (50) | 100 | 50/50 | 4.1 (50) | 103 | 50/50 | 4.2 (49) | 105 | 49/50 | 49/50 |
| 11-7 | 4.1 (50) | 50/50 | 3.9 (50) | 95 | 50/50 | 3.9 (50) | 95 | 50/50 | 4.1 (49) | 100 | 49/50 | 49/50 |
| 12-7 | 4.1 (50) | 50/50 | 4.3 (50) | 105 | 50/50 | 4.3 (50) | 105 | 50/50 | 4.4 (49) | 107 | 49/50 | 49/50 |
| 13-7 | 4.1 (50) | 50/50 | 4.3 (50) | 105 | 50/50 | 4.1 (50) | 100 | 50/50 | 4.2 (49) | 102 | 49/50 | 49/50 |
| 14-7 | 3.8 (50) | 50/50 | 4.1 (50) | 108 | 50/50 | 4.0 (50) | 105 | 50/50 | 3.9 (49) | 103 | 49/50 | 49/50 |
| 18-7 | 4.4 (50) | 50/50 | 4.3 (50) | 98 | 50/50 | 4.5 (50) | 102 | 50/50 | 4.6 (49) | 105 | 49/50 | 49/50 |
| 22-7 | 4.3 (50) | 50/50 | 4.1 (50) | 95 | 50/50 | 4.1 (50) | 95 | 50/50 | 4.1 (49) | 95 | 49/50 | 49/50 |
| 26-7 | 4.5 (50) | 50/50 | 4.5 (49) | 100 | 49/50 | 4.3 (50) | 96 | 50/50 | 4.3 (49) | 96 | 49/50 | 49/50 |
| 30-7 | 4.6 (50) | 50/50 | 4.6 (49) | 100 | 49/50 | 4.6 (50) | 100 | 49/50 | 4.6 (49) | 100 | 49/50 | 49/50 |
| 34-7 | 4.3 (49) | 49/50 | 4.5 (49) | 105 | 49/50 | 4.4 (50) | 102 | 50/50 | 4.4 (49) | 102 | 49/50 | 49/50 |
| 38-7 | 4.2 (49) | 49/50 | 4.4 (49) | 105 | 49/50 | 4.2 (50) | 100 | 50/50 | 4.4 (49) | 105 | 49/50 | 49/50 |
| 42-7 | 4.6 (49) | 49/50 | 4.6 (49) | 100 | 49/50 | 4.7 (50) | 102 | 50/50 | 4.8 (48) | 104 | 48/50 | 48/50 |
| 46-7 | 4.5 (48) | 48/50 | 4.5 (49) | 100 | 49/50 | 4.5 (50) | 100 | 50/50 | 4.3 (48) | 96 | 48/50 | 48/50 |
| 50-7 | 4.7 (48) | 48/50 | 4.5 (49) | 96 | 49/50 | 4.3 (50) | 91 | 50/50 | 4.6 (48) | 98 | 48/50 | 48/50 |
| 54-7 | 5.0 (48) | 48/50 | 5.0 (49) | 100 | 49/50 | 4.8 (50) | 96 | 50/50 | 4.9 (47) | 98 | 47/50 | 47/50 |
| 58-7 | 4.6 (47) | 47/50 | 4.6 (49) | 100 | 49/50 | 4.8 (49) | 104 | 49/50 | 4.6 (47) | 100 | 47/50 | 47/50 |
| 62-7 | 4.7 (47) | 47/50 | 4.5 (49) | 96 | 49/50 | 4.9 (48) | 104 | 48/50 | 4.7 (47) | 100 | 47/50 | 47/50 |
| 66-7 | 4.9 (45) | 45/50 | 4.9 (47) | 100 | 48/50 | 4.9 (47) | 100 | 47/50 | 5.2 (47) | 106 | 47/50 | 47/50 |
| 70-7 | 5.0 (43) | 43/50 | 5.0 (46) | 100 | 48/50 | 5.0 (46) | 100 | 46/50 | 5.0 (46) | 100 | 47/50 | 47/50 |
| 74-7 | 4.9 (43) | 43/50 | 4.9 (46) | 100 | 46/50 | 5.0 (45) | 102 | 45/50 | 4.9 (44) | 100 | 47/50 | 47/50 |
| 78-7 | 5.4 (43) | 43/50 | 5.1 (45) | 94 | 45/50 | 5.0 (44) | 93 | 45/50 | 5.3 (47) | 98 | 47/50 | 47/50 |
| 82-7 | 5.0 (43) | 43/50 | 5.0 (44) | 100 | 45/50 | 4.8 (44) | 96 | 44/50 | 5.0 (44) | 100 | 45/50 | 45/50 |
| 86-7 | 4.8 (40) | 40/50 | 4.8 (44) | 100 | 45/50 | 4.9 (42) | 102 | 43/50 | 5.1 (43) | 106 | 45/50 | 45/50 |
| 90-7 | 5.6 (37) | 37/50 | 5.3 (43) | 95 | 43/50 | 5.4 (41) | 96 | 41/50 | 5.6 (41) | 100 | 42/50 | 42/50 |
| 94-7 | 5.1 (37) | 37/50 | 5.0 (40) | 98 | 40/50 | 4.6 (38) | 90 | 40/50 | 4.6 (38) | 90 | 40/50 | 40/50 |
| 98-7 | 4.9 (34) | 34/50 | 5.0 (37) | 102 | 38/50 | 4.6 (37) | 94 | 38/50 | 4.7 (35) | 96 | 38/50 | 38/50 |
| 102-7 | 5.3 (33) | 33/50 | 5.4 (35) | 102 | 35/50 | 5.2 (37) | 98 | 35/50 | 5.3 (36) | 100 | 36/50 | 36/50 |
| 104-7 | 4.7 (32) | 33/50 | 4.7 (34) | 100 | 34/50 | 5.1 (35) | 109 | 36/50 | 5.0 (34) | 106 | 35/50 | 35/50 |

< >:No. of effective animals, () :No. of measured animals

Av. FC. : g

TABLE D 2

FOOD CONSUMPTION CHANGES AND
SURVIVAL ANIMAL NUMBERS: FEMALE

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/Cr1j[Crl-BDF1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

PAGE : 2

| Week-Day on Study | Control | | | 512 ppm | | | 1280 ppm | | | 3200 ppm | | |
|----------------------|----------|---------------------------|----------|-----------------------|-------------------|----------|-----------------------|-------------------|----------|-----------------------|-------------------|--|
| | Av. FC. | No. of Surviv. <50> | Av. FC. | % of cont. <50> | No. of Surviv. | Av. FC. | % of cont. <50> | No. of Surviv. | Av. FC. | % of cont. <50> | No. of Surviv. | |
| 1-7 | 3.8 (50) | 50/50 | 3.8 (50) | 100 | 50/50 | 3.7 (50) | 97 | 50/50 | 3.8 (50) | 100 | 50/50 | |
| 2-7 | 3.5 (50) | 50/50 | 3.6 (50) | 103 | 50/50 | 3.4 (50) | 97 | 50/50 | 3.5 (50) | 100 | 50/50 | |
| 3-7 | 3.6 (50) | 50/50 | 3.6 (50) | 100 | 50/50 | 3.7 (50) | 103 | 50/50 | 3.5 (50) | 97 | 50/50 | |
| 4-7 | 3.4 (50) | 50/50 | 3.5 (50) | 103 | 50/50 | 3.4 (50) | 100 | 50/50 | 3.4 (50) | 100 | 50/50 | |
| 5-7 | 3.6 (50) | 50/50 | 3.5 (50) | 97 | 50/50 | 3.5 (50) | 97 | 50/50 | 3.5 (50) | 97 | 50/50 | |
| 6-7 | 3.7 (50) | 50/50 | 3.8 (50) | 103 | 50/50 | 3.7 (50) | 100 | 50/50 | 3.7 (50) | 100 | 50/50 | |
| 7-7 | 3.5 (50) | 50/50 | 3.7 (50) | 106 | 50/50 | 3.7 (50) | 106 | 50/50 | 3.6 (50) | 103 | 50/50 | |
| 8-7 | 3.8 (50) | 50/50 | 3.8 (50) | 100 | 50/50 | 3.8 (50) | 103 | 50/50 | 3.9 (50) | 103 | 50/50 | |
| 9-7 | 3.9 (50) | 50/50 | 4.1 (50) | 105 | 50/50 | 4.0 (50) | 103 | 50/50 | 3.8 (50) | 97 | 50/50 | |
| 10-7 | 3.7 (50) | 50/50 | 4.0 (50) | 108 | 50/50 | 3.8 (50) | 103 | 50/50 | 3.8 (50) | 103 | 50/50 | |
| 11-7 | 3.9 (50) | 50/50 | 3.9 (49) | 100 | 50/50 | 3.8 (50) | 97 | 50/50 | 3.8 (50) | 97 | 50/50 | |
| 12-7 | 4.0 (50) | 50/50 | 4.1 (50) | 103 | 50/50 | 4.1 (50) | 103 | 50/50 | 4.0 (50) | 100 | 50/50 | |
| 13-7 | 4.1 (50) | 50/50 | 4.1 (50) | 100 | 50/50 | 4.3 (50) | 105 | 50/50 | 4.0 (50) | 98 | 50/50 | |
| 14-7 | 4.0 (50) | 50/50 | 4.0 (50) | 100 | 50/50 | 4.0 (50) | 100 | 50/50 | 3.8 (50) | 95 | 50/50 | |
| 18-7 | 4.3 (50) | 50/50 | 4.3 (50) | 100 | 50/50 | 4.5 (50) | 105 | 50/50 | 4.3 (50) | 100 | 50/50 | |
| 22-7 | 4.4 (50) | 50/50 | 4.5 (50) | 102 | 50/50 | 4.6 (50) | 105 | 50/50 | 4.5 (49) | 102 | 49/50 | |
| 26-7 | 4.6 (50) | 50/50 | 4.5 (50) | 98 | 50/50 | 4.5 (50) | 98 | 50/50 | 4.3 (49) | 93 | 49/50 | |
| 30-7 | 4.9 (50) | 50/50 | 4.9 (50) | 100 | 50/50 | 5.1 (50) | 104 | 50/50 | 4.8 (49) | 98 | 49/50 | |
| 34-7 | 4.5 (49) | 50/50 | 4.8 (50) | 107 | 50/50 | 4.9 (50) | 109 | 50/50 | 4.3 (49) | 96 | 49/50 | |
| 38-7 | 4.5 (50) | 50/50 | 4.3 (50) | 96 | 50/50 | 4.6 (50) | 102 | 50/50 | 4.7 (49) | 104 | 49/50 | |
| 42-7 | 5.2 (50) | 50/50 | 5.4 (50) | 104 | 50/50 | 5.3 (50) | 102 | 50/50 | 5.2 (48) | 100 | 48/50 | |
| 46-7 | 4.8 (49) | 50/50 | 4.7 (50) | 98 | 50/50 | 4.6 (50) | 96 | 50/50 | 4.9 (48) | 102 | 48/50 | |
| 50-7 | 4.8 (49) | 50/50 | 4.8 (49) | 100 | 50/50 | 4.6 (47) | 96 | 50/50 | 4.8 (46) | 100 | 48/50 | |
| 54-7 | 5.3 (50) | 50/50 | 5.4 (50) | 102 | 50/50 | 5.5 (50) | 104 | 50/50 | 5.3 (48) | 100 | 48/50 | |
| 58-7 | 5.3 (50) | 50/50 | 5.1 (49) | 96 | 49/50 | 5.0 (50) | 94 | 50/50 | 4.8 (48) | 91 | 48/50 | |
| 62-7 | 4.7 (49) | 50/50 | 4.7 (48) | 100 | 48/50 | 4.7 (49) | 100 | 49/50 | 5.2 (48) | 111 | 48/50 | |
| 66-7 | 5.2 (48) | 49/50 | 5.4 (47) | 104 | 47/50 | 5.2 (48) | 100 | 49/50 | 5.3 (47) | 102 | 48/50 | |
| 70-7 | 4.9 (48) | 49/50 | 4.8 (47) | 98 | 47/50 | 4.8 (48) | 98 | 49/50 | 5.2 (47) | 106 | 47/50 | |
| 74-7 | 5.2 (48) | 49/50 | 5.5 (47) | 106 | 47/50 | 5.2 (48) | 100 | 48/50 | 5.2 (45) | 100 | 47/50 | |
| 78-7 | 5.2 (47) | 48/50 | 5.6 (45) | 108 | 46/50 | 5.4 (47) | 104 | 47/50 | 5.3 (46) | 102 | 46/50 | |
| 82-7 | 5.2 (47) | 48/50 | 5.8 (44) | 112 | 44/50 | 4.9 (46) | 94 | 47/50 | 5.2 (43) | 100 | 44/50 | |
| 86-7 | 4.5 (46) | 47/50 | 5.2 (42) | 116 | 43/50 | 4.8 (43) | 107 | 44/50 | 5.1 (40) | 113 | 41/50 | |
| 90-7 | 5.3 (44) | 45/50 | 5.6 (37) | 106 | 41/50 | 5.5 (38) | 104 | 40/50 | 5.8 (36) | 109 | 38/50 | |
| 94-7 | 4.9 (39) | 41/50 | 5.1 (39) | 104 | 39/50 | 5.5 (34) | 112 | 36/50 | 5.4 (34) | 110 | 36/50 | |
| 98-7 | 5.3 (36) | 36/50 | 5.3 (34) | 100 | 34/50 | 5.3 (32) | 100 | 33/50 | 5.5 (34) | 104 | 34/50 | |
| 102-7 | 5.6 (34) | 34/50 | 6.2 (28) | 111 | 29/50 | 5.9 (28) | 105 | 30/50 | 6.0 (29) | 107 | 30/50 | |
| 104-7 | 4.6 (32) | 34/50 | 4.8 (27) | 104 | 28/50 | 5.4 (26) | 117 | 28/50 | 5.4 (28) | 117 | 30/50 | |

< >:No. of effective animals, ():No. of measured animals Av.FC. : g

(B10040)

BAIS 4

TABLE D 3

FOOD CONSUMPTION CHANGES: MALE

| Group Name | Administration week-day(effective) | | | | | | |
|---|------------------------------------|----------|----------|----------|----------|----------|-----------------|
| | 1-7(4) | 2-7(4) | 3-7(4) | 4-7(4) | 5-7(4) | 6-7(4) | 7-7(4) |
| Control | 4.2± 0.5 | 3.8± 0.5 | 3.9± 0.5 | 4.0± 0.5 | 4.0± 0.5 | 3.9± 0.4 | 4.0± 0.5 |
| 512 ppm | 4.1± 0.4 | 4.0± 0.5 | 3.9± 0.5 | 3.9± 0.6 | 3.9± 0.5 | 4.0± 0.5 | 4.0± 0.6 |
| 1280 ppm | 4.0± 0.5 | 3.8± 0.6 | 4.0± 0.5 | 4.0± 0.5 | 4.0± 0.5 | 3.9± 0.4 | 4.0± 0.6 |
| 3200 ppm | 4.0± 0.7 | 4.0± 0.7 | 4.1± 0.6 | 3.9± 0.7 | 4.1± 0.6 | 4.1± 0.6 | 4.1± 0.6 |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | Test of Dunnett |
| (HAN260) | | | | | | | BATS 4 |

| Group Name | Administration week day(effective) | | | | | | |
|------------|------------------------------------|----------|----------|----------|----------|----------|----------|
| | 8-7(4) | 9-7(4) | 10-7(4) | 11-7(4) | 12-7(4) | 13-7(4) | 14-7(4) |
| Control | 4.0± 0.4 | 4.0± 0.4 | 4.0± 0.6 | 4.1± 0.6 | 4.1± 0.4 | 4.1± 0.4 | 3.8± 0.6 |
| 512 ppm | 4.0± 0.5 | 4.1± 0.4 | 4.0± 0.6 | 3.9± 0.7 | 4.3± 0.4 | 4.3± 0.5 | 4.1± 0.6 |
| 1280 ppm | 3.9± 0.7 | 4.2± 0.4 | 4.1± 0.4 | 3.9± 0.5 | 4.3± 0.5 | 4.1± 0.5 | 4.0± 0.6 |
| 3200 ppm | 3.9± 0.8 | 4.1± 0.5 | 4.2± 0.6 | 4.1± 0.6 | 4.4± 0.6 | 4.2± 0.4 | 3.9± 0.7 |

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HAN260)

BATS 4

PAGE : 3

(HAN260)

| Group Name | Administration week day(effective) | | | | | |
|---|------------------------------------|-----------|----------|----------|----------|----------|
| | 46-7(4) | 50-7(4) | 54-7(4) | 58-7(4) | 62-7(4) | 70-7(4) |
| Control | 4.5± 0.7 | 4.7± 0.6 | 5.0± 0.7 | 4.6± 0.9 | 4.7± 1.0 | 5.0± 1.0 |
| 512 ppm | 4.5± 0.5 | 4.5± 0.9 | 5.0± 0.7 | 4.6± 0.7 | 4.5± 1.0 | 5.0± 0.6 |
| 1280 ppm | 4.5± 0.6 | 4.3± 0.9* | 4.8± 0.9 | 4.8± 0.7 | 4.9± 0.8 | 5.0± 0.9 |
| 3200 ppm | 4.3± 0.8 | 4.6± 0.8 | 4.9± 0.5 | 4.6± 1.0 | 4.7± 1.1 | 5.0± 0.8 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | |
| Test of Dunnett | | | | | | |
| (HAN260) | | | | | | BATS 4 |

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/Cr1J[Crj:BDP1]

UNIT : g

REPORT TYPE : A1 104

SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)

ALL ANIMALS

PAGE : 5

| Group Name | Administration week day(effective) | | | | |
|------------|------------------------------------|----------|----------|----------|----------|
| | 74-7(4) | 78-7(4) | 82-7(4) | 86-7(4) | 90-7(4) |
| Control | 4.9± 0.7 | 5.4± 0.7 | 5.0± 1.0 | 4.8± 1.4 | 5.6± 0.9 |
| 512 ppm | 4.9± 0.8 | 5.1± 0.8 | 5.0± 1.3 | 4.8± 1.2 | 5.3± 1.0 |
| 1280 ppm | 5.0± 1.1 | 5.0± 0.8 | 4.8± 1.0 | 4.9± 1.0 | 5.4± 1.1 |
| 3200 ppm | 4.9± 1.1 | 5.3± 0.9 | 5.0± 1.1 | 5.1± 1.3 | 5.6± 1.1 |
| | | | | 4.6± 1.3 | 4.7± 1.2 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HAN260)

BATS 4

| Group Name | Administration 102-7(4) | week-day(effective) 104-7(4) |
|------------|----------------------------|---------------------------------|
| Control | 5.3± 1.2 | 4.7± 1.6 |
| 512 ppm | 5.4± 1.2 | 4.7± 1.5 |
| 1280 ppm | 5.2± 1.2 | 5.1± 1.3 |
| 3200 ppm | 5.3± 1.4 | 5.0± 1.2 |

Significant difference :
* : $P \leq 0.05$
** : $P \leq 0.01$

Test of Dunnett

(HAN260)

BATS 4

TABLE D 4

FOOD CONSUMPTION CHANGES: FEMALE

| Group Name | Administration week day(effective) | | | | | | |
|---|------------------------------------|----------|----------|----------|----------|----------|----------|
| | 1-7(4) | 2-7(4) | 3-7(4) | 4-7(4) | 5-7(4) | 6-7(4) | 7-7(4) |
| Control | 3.8± 0.6 | 3.5± 0.5 | 3.6± 0.6 | 3.4± 0.6 | 3.6± 0.6 | 3.7± 0.6 | 3.5± 0.5 |
| 512 ppm | 3.8± 0.6 | 3.6± 0.5 | 3.6± 0.6 | 3.5± 0.5 | 3.5± 0.4 | 3.8± 0.5 | 3.7± 0.6 |
| 1280 ppm | 3.7± 0.5 | 3.4± 0.6 | 3.7± 0.6 | 3.4± 0.5 | 3.5± 0.6 | 3.7± 0.5 | 3.7± 0.5 |
| 3200 ppm | 3.9± 0.6 | 3.5± 0.6 | 3.5± 0.6 | 3.4± 0.5 | 3.5± 0.4 | 3.7± 0.5 | 3.6± 0.5 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | |
| Test of Dunnett | | | | | | | |
| (HAN260) | | | | | | | BATS 4 |

| Group Name | Administration week-day(effective) | | | | | | |
|------------|------------------------------------|----------|----------|----------|----------|----------|----------|
| | 8-7(4) | 9-7(4) | 10-7(4) | 11-7(4) | 12-7(4) | 13-7(4) | 14-7(4) |
| Control | 3.8± 0.7 | 3.9± 0.6 | 3.7± 0.7 | 3.9± 0.6 | 4.0± 0.6 | 4.1± 0.7 | 4.0± 0.8 |
| 512 ppm | 3.8± 0.5 | 4.1± 0.5 | 4.0± 0.6 | 3.9± 0.6 | 4.1± 0.7 | 4.1± 0.7 | 4.0± 0.6 |
| 1280 ppm | 3.8± 0.7 | 4.0± 0.7 | 3.8± 0.6 | 3.8± 0.7 | 4.1± 0.8 | 4.3± 1.0 | 4.0± 0.9 |
| 3200 ppm | 3.9± 0.5 | 3.8± 0.4 | 3.8± 0.6 | 3.8± 0.5 | 4.0± 0.6 | 4.0± 0.6 | 3.8± 0.6 |

Significant difference :
* : $P \leq 0.05$
** : $P \leq 0.01$

Test of Dunnett

(HAN260)

BATS 4

| Group Name | Administration 18-7(4) | week-day(effective) 22-7(4) | 26-7(4) | 30-7(4) | 34-7(4) | 38-7(4) | 42-7(4) |
|------------|---------------------------|--------------------------------|----------|----------|----------|----------|----------|
| Control | 4.3± 0.7 | 4.4± 1.0 | 4.6± 1.0 | 4.9± 0.9 | 4.5± 1.0 | 4.5± 1.1 | 5.2± 1.0 |
| 512 ppm | 4.3± 0.7 | 4.5± 0.7 | 4.5± 1.0 | 4.9± 1.0 | 4.8± 1.0 | 4.3± 0.9 | 5.4± 1.0 |
| 1280 ppm | 4.5± 1.0 | 4.6± 1.1 | 4.5± 1.2 | 5.1± 1.1 | 4.9± 1.2 | 4.6± 1.3 | 5.3± 1.2 |
| 3200 ppm | 4.3± 0.9 | 4.5± 0.9 | 4.3± 0.8 | 4.8± 0.9 | 4.3± 0.8 | 4.7± 1.1 | 5.2± 1.1 |

| Significant difference ; | * : P ≤ 0.05 | ** : P ≤ 0.01 | Test of Dunnett |
|--------------------------|--------------|---------------|-----------------|
| (HAN260) | | | BATS 4 |

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
UNIT : g
REPORT TYPE : A1 104
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

PAGE : 10

| Group Name | Administration week-day(effective) | | | | | | |
|--|------------------------------------|----------|----------|----------|----------|----------|-----------------|
| | 46-7(4) | 50-7(4) | 54-7(4) | 58-7(4) | 62-7(4) | 66-7(4) | 70-7(4) |
| Control | 4.8± 1.2 | 4.8± 1.2 | 5.3± 1.2 | 5.3± 1.5 | 4.7± 1.2 | 5.2± 1.1 | 4.9± 1.3 |
| 512 ppm | 4.7± 1.1 | 4.8± 1.0 | 5.4± 0.9 | 5.1± 1.3 | 4.7± 1.0 | 5.4± 1.1 | 4.8± 1.3 |
| 1280 ppm | 4.6± 1.2 | 4.6± 1.3 | 5.5± 1.3 | 5.0± 1.4 | 4.7± 1.3 | 5.2± 1.2 | 4.8± 1.4 |
| 3200 ppm | 4.9± 1.1 | 4.8± 1.0 | 5.3± 1.0 | 4.8± 1.3 | 5.2± 1.0 | 5.3± 1.1 | 5.2± 1.1 |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | Test of Dunnett |
| (HAN260) | | | | | | | BAIS 4 |

| Group Name | Administration week-day(effective) | | | | | | Test of Dunnett | BATS 4 |
|---|------------------------------------|----------|----------|----------|----------|----------|-----------------|--------|
| | 74-7(4) | 78-7(4) | 82-7(4) | 86-7(4) | 90-7(4) | 94-7(4) | | |
| Control | 5.2± 1.4 | 5.2± 1.2 | 5.2± 1.3 | 4.5± 1.6 | 5.3± 1.5 | 4.9± 1.8 | 5.3± 1.5 | |
| 512 ppm | 5.5± 1.4 | 5.6± 1.0 | 5.8± 1.3 | 5.2± 1.2 | 5.6± 1.1 | 5.1± 1.6 | 5.3± 1.1 | |
| 1280 ppm | 5.2± 1.3 | 5.4± 1.2 | 4.9± 1.4 | 4.8± 1.4 | 5.5± 1.4 | 5.5± 1.5 | 5.3± 1.5 | |
| 3200 ppm | 5.2± 1.4 | 5.3± 1.2 | 5.2± 1.3 | 5.1± 1.7 | 5.8± 1.2 | 5.4± 1.4 | 5.5± 1.6 | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | | |
| (HAN260) | | | | | | | | |

| Group Name | Administration 102-7(4) | week-day(effective) 104-7(4) | | |
|---|----------------------------|---------------------------------|--|--------|
| Control | 5.6± 1.6 | 4.6± 1.0 | | |
| 512 ppm | 6.2± 1.2 | 4.8± 1.3 | | |
| 1280 ppm | 5.9± 1.5 | 5.4± 1.2 | | |
| 3200 ppm | 6.0± 1.5 | 5.4± 1.3* | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | |
| (HAN260) | | | | BATS-4 |

TABLE E 1

CHEMICAL INTAKE CHANGES: MALE

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.083± 0.008 | 0.079± 0.009 | 0.074± 0.008 | 0.071± 0.009 | 0.070± 0.007 | 0.069± 0.008 | 0.068± 0.010 |
| 1280 ppm | 0.204± 0.023 | 0.189± 0.027 | 0.189± 0.025 | 0.182± 0.025 | 0.179± 0.023 | 0.171± 0.017 | 0.171± 0.024 |
| 3200 ppm | 0.515± 0.076 | 0.495± 0.082 | 0.490± 0.070 | 0.459± 0.069 | 0.457± 0.066 | 0.453± 0.061 | 0.437± 0.066 |
| (HAN300) | | | | | | | |
| BALS 4 | | | | | | | |

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.067± 0.008 | 0.066± 0.007 | 0.064± 0.009 | 0.062± 0.010 | 0.065± 0.007 | 0.064± 0.008 | 0.059± 0.008 |
| 1280 ppm | 0.163± 0.027 | 0.169± 0.018 | 0.164± 0.017 | 0.153± 0.021 | 0.162± 0.017 | 0.153± 0.019 | 0.145± 0.021 |
| 3200 ppm | 0.413± 0.070 | 0.425± 0.053 | 0.420± 0.056 | 0.410± 0.059 | 0.423± 0.058 | 0.395± 0.039 | 0.362± 0.065 |
| (HAN300) | | | | | | | |
| BALS 4 | | | | | | | |

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| | 18 | 22 | 26 | 30 | 34 | 38 | 42 |
| Control | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 512 ppm | 0.059 ± 0.006 | 0.053 ± 0.007 | 0.055 ± 0.007 | 0.053 ± 0.007 | 0.050 ± 0.006 | 0.048 ± 0.006 | 0.049 ± 0.007 |
| 1280 ppm | 0.152 ± 0.017 | 0.134 ± 0.022 | 0.133 ± 0.017 | 0.135 ± 0.014 | 0.126 ± 0.020 | 0.117 ± 0.022 | 0.127 ± 0.015 |
| 3200 ppm | 0.390 ± 0.042 | 0.338 ± 0.052 | 0.332 ± 0.045 | 0.348 ± 0.057 | 0.321 ± 0.055 | 0.309 ± 0.048 | 0.323 ± 0.050 |

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|---------------|---------------|---------------|---------------|---------------|---------------|
| | 46 | 50 | 54 | 58 | 62 | 66 | 70 |
| Control | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 512 ppm | 0.046 ± 0.005 | 0.047 ± 0.009 | 0.050 ± 0.008 | 0.046 ± 0.008 | 0.045 ± 0.009 | 0.048 ± 0.007 | 0.048 ± 0.006 |
| 1280 ppm | 0.118 ± 0.019 | 0.112 ± 0.020 | 0.122 ± 0.023 | 0.120 ± 0.018 | 0.120 ± 0.021 | 0.122 ± 0.021 | 0.122 ± 0.024 |
| 3200 ppm | 0.285 ± 0.051 | 0.300 ± 0.049 | 0.308 ± 0.043 | 0.293 ± 0.058 | 0.296 ± 0.072 | 0.323 ± 0.078 | 0.306 ± 0.060 |

| Group Name | Administration (weeks) | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|
| | 74 | 78 | 82 | 86 | 90 |
| | | | | | 94 |
| | | | | | 98 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.047± 0.007 | 0.048± 0.007 | 0.048± 0.012 | 0.047± 0.012 | 0.046± 0.009 |
| 1280 ppm | 0.122± 0.025 | 0.122± 0.022 | 0.117± 0.025 | 0.122± 0.027 | 0.113± 0.031 |
| 3200 ppm | 0.295± 0.068 | 0.322± 0.053 | 0.298± 0.068 | 0.305± 0.079 | 0.278± 0.079 |
| (HAN300) | | | | | |
| BALB 4 | | | | | |

CHEMICAL INTAKE CHANGES (SUMMARY)
ALL ANIMALS

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:DDF1]
UNIT : g/kg/d a y
REPORT TYPE : A1 104
SEX : MALE

| Group Name | Administration (weeks) | |
|------------|------------------------|---------------|
| | 102 | 104 |
| Control | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 512 ppm | 0.051 ± 0.012 | 0.046 ± 0.016 |
| 1280 ppm | 0.141 ± 0.047 | 0.138 ± 0.050 |
| 3200 ppm | 0.328 ± 0.092 | 0.320 ± 0.118 |

TABLE E 2

CHEMICAL INTAKE CHANGES: FEMALE

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.096± 0.015 | 0.090± 0.013 | 0.089± 0.014 | 0.083± 0.012 | 0.082± 0.010 | 0.088± 0.011 | 0.083± 0.012 |
| 1280 ppm | 0.238± 0.024 | 0.213± 0.030 | 0.224± 0.037 | 0.204± 0.031 | 0.204± 0.033 | 0.214± 0.031 | 0.209± 0.027 |
| 3200 ppm | 0.624± 0.094 | 0.554± 0.090 | 0.547± 0.081 | 0.514± 0.071 | 0.505± 0.058 | 0.534± 0.059 | 0.500± 0.066 |
| (HM300) | | | | | | | |
| | | | | | | | BALS 4 |

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.082± 0.011 | 0.086± 0.011 | 0.084± 0.011 | 0.081± 0.011 | 0.083± 0.011 | 0.082± 0.014 | 0.079± 0.012 |
| 1280 ppm | 0.242± 0.038 | 0.215± 0.037 | 0.205± 0.032 | 0.204± 0.040 | 0.212± 0.039 | 0.218± 0.050 | 0.199± 0.043 |
| 3200 ppm | 0.529± 0.060 | 0.510± 0.050 | 0.508± 0.059 | 0.501± 0.059 | 0.520± 0.065 | 0.512± 0.068 | 0.476± 0.065 |

| Group Name | Administration (weeks) | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|
| | 46 | 50 | 54 | 58 | 62 | 70 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.063± 0.013 | 0.064± 0.013 | 0.069± 0.013 | 0.066± 0.015 | 0.060± 0.012 | 0.060± 0.016 |
| 1280 ppm | 0.163± 0.040 | 0.162± 0.044 | 0.182± 0.045 | 0.167± 0.041 | 0.157± 0.037 | 0.157± 0.042 |
| 3200 ppm | 0.421± 0.087 | 0.411± 0.078 | 0.429± 0.061 | 0.389± 0.084 | 0.415± 0.067 | 0.413± 0.080 |
| (HAN300) | | | | | | |
| | | | | | | BALS 4 |

| Group Name | Administration (weeks) | | | | | | |
|------------|------------------------|--------------|--------------|--------------|--------------|--------------|--------------|
| | 74 | 78 | 82 | 86 | 90 | 94 | 98 |
| Control | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.068± 0.016 | 0.069± 0.015 | 0.071± 0.019 | 0.062± 0.014 | 0.068± 0.016 | 0.064± 0.020 | 0.065± 0.016 |
| 1280 ppm | 0.167± 0.036 | 0.173± 0.037 | 0.159± 0.042 | 0.152± 0.041 | 0.171± 0.040 | 0.175± 0.050 | 0.166± 0.043 |
| 3200 ppm | 0.411± 0.100 | 0.411± 0.094 | 0.407± 0.093 | 0.404± 0.125 | 0.457± 0.097 | 0.433± 0.101 | 0.441± 0.111 |
| (HAN300) | | | | | | | |
| | | | | | | | BALS 4 |

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crj:EDF1]
UNIT : g/kg/d a y
REPORT TYPE : A1 104
SEX : FEMALE

CHEMICAL INTAKE CHANGES
ALL ANIMALS

(SUMMARY)

| Group Name | Administration (weeks) | |
|------------|------------------------|--------------|
| | 102 | 104 |
| Control | 0.000± 0.000 | 0.000± 0.000 |
| 512 ppm | 0.078± 0.017 | 0.064± 0.020 |
| 1280 ppm | 0.183± 0.050 | 0.173± 0.040 |
| 3200 ppm | 0.498± 0.103 | 0.464± 0.115 |
| (HAN300) | | |
| BALS 4 | | |

TABLE F 1

HEMATOLOGY: MALE

| HEMATOLOGY (SUMMARY) | | | | | | | | | PAGE : 1 |
|---|----------------|--|--------------------|-----------------|------------|------------|--------------|----------------------------------|----------|
| ALL ANIMALS (105W) | | | | | | | | | |
| Group Name | NO. of Animals | RED BLOOD CELL 1 0 ⁶ /μl | HEMOGLOBIN g/dl | HEMATOCRIT % | MCV f l | MCH p g | MCHC g/dl | PLATELET 1 0 ³ /μl | |
| Control | 33 | 9.73± 1.52 | 13.8± 1.9 | 40.8± 4.9 | 42.2± 2.5 | 14.3± 0.8 | 33.9± 1.1 | 1530± 441 | |
| 512 ppm | 34 | 9.57± 0.96 | 14.0± 1.3 | 41.0± 3.8 | 42.9± 2.2 | 14.6± 0.8 | 34.1± 0.9 | 1660± 341 | |
| 1280 ppm | 35 | 9.23± 1.44 | 13.4± 2.0 | 39.3± 5.3 | 42.9± 3.5 | 14.5± 1.0 | 33.9± 1.3 | 1601± 429 | |
| 3200 ppm | 35 | 9.39± 1.56 | 13.6± 2.1 | 40.1± 5.1 | 43.3± 4.0 | 14.5± 0.7 | 33.7± 1.9 | 1667± 348 | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett | | | | | | | | | |
| BALS 4 | | | | | | | | | |

| Group Name | No. of Animals | RETICULOCYTE % | |
|------------|-------------------|-------------------|-----|
| Control | 33 | 3.3± | 3.5 |
| 512 ppm | 34 | 2.5± | 1.0 |
| 1280 ppm | 35 | 3.5± | 3.5 |
| 3200 ppm | 35 | 4.2± | 7.6 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL070)

BALS 4

| Group Name | NO. of Animals | WBC 1 C ³ /μℓ | Differential | | WBC N-SEG (%) | EOSINO | BASO | MONO | LYMPHO | OTHER | |
|------------|-------------------|-----------------------------|--------------|---|------------------|--------|------|------|--------|---------|--------|
| | | | N-BAND | | | | | | | | |
| Control | 33 | 3.84 ± 3.68 | 1 ± | 1 | 27 ± 10 | 2 ± 1 | 0 ± | 4 ± | 2 | 63 ± 12 | 2 ± 5 |
| 512 ppm | 34 | 4.19 ± 3.97 | 1 ± | 1 | 25 ± 12 | 2 ± 1 | 0 ± | 4 ± | 2 | 65 ± 16 | 3 ± 13 |
| 1280 ppm | 35 | 5.26 ± 10.39 | 1 ± | 2 | 29 ± 15 | 3 ± 2 | 0 ± | 3 ± | 2 | 60 ± 18 | 4 ± 16 |
| 3200 ppm | 35 | 3.70 ± 1.74 | 1 ± | 1 | 25 ± 13 | 2 ± 1 | 0 ± | 3 ± | 2 | 68 ± 15 | 1 ± 2 |

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett

(HCL070)

BMS 4

TABLE F 2

HEMATOLOGY: FEMALE

| | | | | | | | | | |
|-------------------------------------|----------------|--|--------------------|-----------------|------------|------------|--------------|----------------------------------|----------|
| STUDY NO. : 0580 | | HEMATOLOGY (SUMMARY) | | | | | | | PAGE : 4 |
| ANIMAL : MOUSE B6D2F1/CrJ[Cxj:DDF1] | | ALL ANIMALS (105W) | | | | | | | |
| MEASURE TIME : 1 | | | | | | | | | |
| SEX : FEMALE | | REPORT TYPE : A1 | | | | | | | |
| Group Name | NO. of Animals | RED BLOOD CELL 1 0 ⁶ /μl | HEMOGLOBIN g/dl | HEMATOCRIT % | MCV f l | MCH p g | MCHC g/dl | PLATELET 1 0 ³ /μl | |
| Control | 34 | 9.11± 1.50 | 13.5± 2.0 | 39.9± 4.4 | 44.3± 4.2 | 14.9± 0.8 | 33.9± 1.6 | 1051± 351 | |
| 512 ppm | 28 | 9.66± 0.88 | 14.4± 1.2 | 41.5± 2.7 | 43.1± 2.1 | 14.9± 0.5 | 34.6± 0.9 | 1030± 302 | |
| 1280 ppm | 28 | 9.66± 0.76 | 14.3± 1.1 | 41.1± 2.7 | 42.7± 1.4 | 14.8± 0.4 | 34.8± 0.8** | 1173± 156 | |
| 3200 ppm | 29 | 9.44± 0.64 | 14.0± 1.0 | 40.8± 2.3 | 43.2± 1.4 | 14.9± 0.4 | 34.4± 0.8 | 1138± 298 | |
| Significant difference ; | | * : P ≤ 0.05 | ** : P ≤ 0.01 | Test of Dunnett | | | | | |
| (HCL070) | | | | | | | | | |
| | | BALS 4 | | | | | | | |

| | | | | | | |
|-------------------------------------|-------------------|-------------------|----------------------|---------------|-----------------|----------|
| STUDY NO. : 0580 | | | HEMATOLOGY (SUMMARY) | | | PAGE : 5 |
| ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1] | | | ALL ANIMALS (105W) | | | |
| MEASURE TIME : 1 | | | | | | |
| SEX : FEMALE | | | REPORT TYPE : A1 | | | |
| | | | | | | |
| Group Name | NO. of Animals | RETICULOCYTE % | | | | |
| Control | 34 | 5.2± | 6.3 | | | |
| 512 ppm | 28 | 3.2± | 2.8 | | | |
| 1280 ppm | 28 | 2.6± | 1.0 | | | |
| 3200 ppm | 29 | 3.6± | 1.8 | | | |
| Significant difference ; | | | * : P ≤ 0.05 | ** : P ≤ 0.01 | Test of Dunnett | |
| (HCL070) | | | | | | BALS 4 |

| STUDY NO. : 0580 | | | | HEMATOLOGY (SUMMARY) | | | | PAGE : 6 | | | | | | | | |
|-------------------------------------|----------------|-----------------------------|--------|-------------------------|------------|------|------------|-----------------|-------|---|----|---|-----|----|----|----|
| ANIMAL : MOUSE B6D2F1/CrJ[CxJ:EDF1] | | | | ALL ANIMALS (105W) | | | | | | | | | | | | |
| MEASURE. TIME : 1 | | | | | | | | | | | | | | | | |
| SEX : FEMALE | | | | REPORT TYPE : A1 | | | | | | | | | | | | |
| Group Name | NO. of Animals | WBC 1 O ³ /μl | N-BAND | Differential WBC (%) | EOSINO | BASO | MONO | LYMPHO | OTHER | | | | | | | |
| Control | 34 | 5.11± 6.94 | 1± | 1 | 25± | 15 | 1± | 1 | 0± | 0 | 4± | 2 | 63± | 19 | 6± | 14 |
| 512 ppm | 28 | 27.20± 127.52 | 1± | 1 | 21± | 10 | 2± | 1 | 0± | 0 | 4± | 2 | 68± | 17 | 4± | 19 |
| 1280 ppm | 28 | 3.55± 2.29 | 1± | 1 | 22± | 7 | 2± | 2 | 0± | 0 | 4± | 2 | 69± | 10 | 2± | 7 |
| 3200 ppm | 29 | 2.83± 1.41 | 2± | 1 | 30± | 18 | 2± | 1 | 0± | 0 | 4± | 2 | 59± | 20 | 3± | 6 |
| Significant difference ; | | | | * | : P ≤ 0.05 | ** | : P ≤ 0.01 | Test of Dunnett | | | | | | | | |
| (HCL070) | | | | | | | | | | | | | | | | |
| BALIS 4 | | | | | | | | | | | | | | | | |

TABLE G 1

BIOCHEMISTRY: MALE

| Group Name | NO. of Animals | TOTAL PROTEIN g/dl | ALBUMIN g/dl | A/G RATIO | T-BILIRUBIN mg/dl | GLUCOSE mg/dl | T-CHOLESTEROL mg/dl | TRIGLYCERIDE mg/dl |
|------------|-------------------|-----------------------|-----------------|-----------|----------------------|------------------|------------------------|-----------------------|
| Control | 33 | 5.6± | 2.7± | 1.0± | 0.14± | 178± | 125± | 37± |
| 512 ppm | 34 | 5.4± | 2.7± | 1.0± | 0.13± | 199± | 128± | 50± |
| 1280 ppm | 35 | 5.7± | 2.7± | 1.0± | 0.15± | 177± | 125± | 38± |
| 3200 ppm | 35 | 5.5± | 2.8± | 1.0± | 0.15± | 188± | 140± | 49± |

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01
(HCL074)

Test of Dunnett

BALS 4

| STUDY NO. : 0580 | | | | BIOCHEMISTRY (SUMMARY) | | | | PAGE : 2 | | | |
|---|----------------|--------------------|------------|------------------------|------------|------------|--------------|-----------|-----|----|-----------|
| ANIMAL : MOUSE B6D2F1/CrJ(ICrJ:DDF1] | | | | ALL ANIMALS (105W) | | | | | | | |
| MEASURE. TIME : 1 | | | | | | | | | | | |
| SEX : MALE | | | | REPORT TYPE : A1 | | | | | | | |
| Group Name | NO. of Animals | PHOSPHOLIPID mg/dL | AST IU / ℓ | ALT IU / ℓ | LDH IU / ℓ | ALP IU / ℓ | G-GTP IU / ℓ | CK IU / ℓ | | | |
| Control | 33 | 208± | 83 | 271± | 1033 | 1891± | 8012 | 167± | 119 | 1± | 1 56± 35 |
| 512 ppm | 34 | 218± | 91 | 65± | 106* | 495± | 335 | 153± | 122 | 1± | 1 50± 13 |
| 1280 ppm | 35 | 206± | 144 | 62± | 96 | 473± | 291 | 129± | 33 | 1± | 1 63± 49 |
| 3200 ppm | 35 | 229± | 96 | 114± | 443* | 1578± | 7106 | 151± | 100 | 0± | 1 80± 184 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | | | | | |
| Test of Dunnett | | | | | | | | | | | |
| (HCL074) | | | | | | | | | | | |
| BALS 4 | | | | | | | | | | | |

| Group Name | NO. of Animals | UREA NITROGEN mg/dl | SODIUM mEq/l | POTASSIUM mEq/l | CHLORIDE mEq/l | CALCIUM mg/dl | INORGANIC PHOSPHORUS mg/dl |
|------------|----------------|------------------------|-----------------|--------------------|-------------------|------------------|-------------------------------|
| Control | 33 | 20.0± 3.7 | 153± 1 | 4.2± 0.4 | 120± 2 | 9.3± 0.6 | 6.4± 1.1 |
| 512 ppm | 34 | 23.1± 11.4 | 153± 2 | 4.3± 0.5 | 121± 2 | 9.1± 0.6 | 6.5± 1.0 |
| 1280 ppm | 35 | 26.4± 15.0** | 153± 3 | 4.4± 0.6 | 120± 4 | 9.2± 0.8 | 6.6± 1.3 |
| 3200 ppm | 35 | 26.2± 19.9* | 153± 2 | 4.4± 0.6 | 120± 4 | 9.1± 0.6 | 6.4± 1.0 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HCL074)

BAS4

TABLE G 2

BIOCHEMISTRY: FEMALE

| | | | | | | | | | |
|--|----------------|------------------------|-----------------|-----------|----------------------|------------------|------------------------|-----------------------|--|
| STUDY NO. : 0580 | | BIOCHEMISTRY (SUMMARY) | | | | | | PAGE : 4 | |
| ANIMAL : MOUSE B6D2F1/CrJ[Crj:DDF1] | | ALL ANIMALS (105W) | | | | | | | |
| MEASURE. TIME : 1 | | | | | | | | | |
| SEX : FEMALE | | REPORT TYPE : A1 | | | | | | | |
| Group Name | No. of Animals | TOTAL PROTEIN g/dl | ALBUMIN g/dl | A/G RATIO | T-BILIRUBIN mg/dl | GLUCOSE mg/dl | T-CHOLESTEROL mg/dl | TRIGLYCERIDE mg/dl | |
| Control | 34 | 4.9± 0.6 | 2.5± 0.3 | 1.1± 0.2 | 0.14± 0.05 | 137± 40 | 73± 23 | 31± 14 | |
| 512 ppm | 28 | 4.9± 0.4 | 2.6± 0.2 | 1.1± 0.1 | 0.14± 0.05 | 144± 29 | 71± 18 | 31± 16 | |
| 1280 ppm | 28 | 5.0± 0.6 | 2.6± 0.4 | 1.1± 0.2 | 0.13± 0.02 | 142± 29 | 80± 34 | 30± 14 | |
| 3200 ppm | 30 | 5.2± 0.5 | 2.7± 0.3 | 1.1± 0.1 | 0.13± 0.03 | 145± 37 | 92± 40 | 37± 23 | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | | | |
| Test of Dunnett | | | | | | | | | |
| (HCL074) | | | | | | | | | |
| BALS 4 | | | | | | | | | |

| STUDY NO. : 0580 | | BIOCHEMISTRY (SUMMARY) | | | | | | | | | | PAGE : 5 | |
|--|----------------|------------------------|----------------|----------------|----------------|----------------|------------------|---------------|----|-----------------|---|----------|-----|
| ANIMAL : MOUSE B6D2F1/CrJ[Cxj:EDF1] | | ALL ANIMALS (105W) | | | | | | | | | | | |
| MEASURE TIME : 1 | | | | | | | | | | | | | |
| SEX : FEMALE | | REPORT TYPE : A1 | | | | | | | | | | | |
| Group Name | No. of Animals | PHOSPHOLIPID mg/dl | AST IU / dl | ALT IU / dl | LDH IU / dl | ALP IU / dl | G-GTP IU / dl | CK IU / dl | | | | | |
| Control | 34 | 128± | 39 | 74± | 160 | 711± | 1367 | 224± | 93 | 1± | 1 | 126± | 249 |
| 512 ppm | 28 | 130± | 32 | 58± | 70 | 437± | 476 | 212± | 63 | 1± | 1 | 66± | 50 |
| 1280 ppm | 28 | 138± | 51 | 36± | 15 | 353± | 183 | 198± | 78 | 1± | 1 | 127± | 252 |
| 3200 ppm | 30 | 155± | 39* | 41± | 31 | 449± | 409 | 181± | 75 | 1± | 1 | 85± | 127 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | | | | | | | Test of Dunnett | | | |
| (HCL074) | | | | | | | | | | | | | |
| BALS 4 | | | | | | | | | | | | | |

| BIOCHEMISTRY (SUMMARY) | | | | | | | | PAGE : 6 |
|---|----------------|------------------------|-----------------|--------------------|-------------------|------------------|-------------------------------|----------|
| ALL ANIMALS (105W) | | | | | | | | |
| Group Name | NO. of Animals | UREA NITROGEN mg/dl | SODIUM mEq/l | POTASSIUM mEq/l | CHLORIDE mEq/l | CALCIUM mg/dl | INORGANIC PHOSPHORUS mg/dl | |
| Control | 34 | 20.7 ± | 153 ± | 4.3 ± | 122 ± | 9.0 ± | 6.3 ± | |
| 512 ppm | 28 | 15.8 ± | 152 ± | 4.0 ± | 122 ± | 8.9 ± | 5.8 ± | |
| 1280 ppm | 28 | 18.0 ± | 152 ± | 4.1 ± | 122 ± | 9.0 ± | 6.1 ± | |
| 3200 ppm | 30 | 20.8 ± | 152 ± | 4.2 ± | 121 ± | 9.3 ± | 6.5 ± | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Dunnett | | | | | | | | |
| (HCL074) | | | | | | | | |
| BALS 4 | | | | | | | | |

TABLE H 1

URINALYSIS: MALE

STUDY NO. : 0580
 URINALYSIS

ANIMAL : MOUSE D6D2F1/Cr1J[Crj:BDP1]
 MEASURE. TIME : 1
 SEX : MALE
 REPORT TYPE : A1

PAGE : 2

| Group Name | No. of Animals | Urobilinogen ± 1 2+ 3+ 4+ | CHI |
|------------|-------------------|------------------------------|-----|
| Control | 33 | 33 0 0 0 0 | |
| 512 ppm | 35 | 35 0 0 0 0 | |
| 1280 ppm | 36 | 36 0 0 0 0 | |
| 3200 ppm | 36 | 36 0 0 0 0 | |

Test of CHI SQUARE

** : $P \leq 0.01$

* : $P \leq 0.05$

Significant difference ;

(ICL101)

BAIS 4

TABLE H 2

URINALYSIS: FEMALE

| Group Name | NO. of Animals | pH | | | | | | | | Protein | | Glucose | | Ketone body | | Occult blood | | CHI | | | | | | | | | | |
|------------|-------------------|-----|-----|-----|-----|-----|-----|-----|-----|----------------|-----|----------------|-----|----------------|-----|--------------|---|-----|---|---|---|---|----|----|---|---|---|---|
| | | 5.0 | 6.0 | 6.5 | 7.0 | 7.5 | 8.0 | 8.5 | CHI | — ± + 2+ 3+ 4+ | CHI | — ± + 2+ 3+ 4+ | CHI | — ± + 2+ 3+ 4+ | CHI | — ± + 2+ 3+ | | | | | | | | | | | | |
| Control | 34 | 0 | 4 | 10 | 5 | 7 | 6 | 2 | 0 | 3 | 15 | 14 | 2 | 0 | 34 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 28 | 1 | 0 | 0 | 5 | |
| 512 ppm | 29 | 0 | 1 | 6 | 12 | 4 | 4 | 2 | 0 | 2 | 18 | 8 | 1 | 0 | 29 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 20 | 6 | 0 | 0 | 1 |
| 1280 ppm | 28 | 0 | 0 | 8 | 4 | 9 | 4 | 3 | 0 | 3 | 18 | 6 | 1 | 0 | 28 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 19 | 4 | 2 | 0 | 3 |
| 3200 ppm | 30 | 0 | 0 | 4 | 9 | 7 | 9 | 1 | 1 | 4 | 18 | 6 | 1 | 0 | 30 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 24 | 3 | 1 | 0 | 1 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

(HCL101)

Test of CHI SQUARE

BAS 4

STUDY NO. : 0580
 URINALYSIS

ANIMAL : MOUSE B6D2F1/CrJ[CrJ:EDF1]
 MEASURE TIME : 1
 SEX : FEMALE
 REPORT TYPE : A1

PAGE : 4

| Group Name | NO. of Animals | Urobilinogen ± + 2+ 3+ 4+ | CHI |
|------------|-------------------|------------------------------|-----|
| Control | 34 | 34 0 0 0 0 | |
| 512 ppm | 29 | 29 0 0 0 0 | |
| 1280 ppm | 28 | 28 0 0 0 0 | |
| 3200 ppm | 30 | 30 0 0 0 0 | |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of CHI SQUARE

(ICL101)

BALS 4

TABLE J 1

ORGAN WEIGHT, ABSOLUTE: MALE

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crj:HDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 1

| Group Name | NO. of Animals | Body Weight | ADRENALS | TESTES | HEART | LUNGS | KIDNEYS |
|------------|----------------|-------------|--------------|--------------|---------------|---------------|---------------|
| Control | 33 | 45.5± 8.2 | 0.010± 0.001 | 0.222± 0.028 | 0.220± 0.025 | 0.207 ± 0.050 | 0.640± 0.167 |
| 512 ppm | 34 | 49.8± 7.1 | 0.010± 0.001 | 0.222± 0.030 | 0.215 ± 0.020 | 0.213± 0.070 | 0.665 ± 0.373 |
| 1280 ppm | 36 | 45.8± 8.8 | 0.010± 0.002 | 0.222± 0.029 | 0.219± 0.025 | 0.211 ± 0.059 | 0.724± 0.479 |
| 3200 ppm | 35 | 48.5± 7.2 | 0.012± 0.012 | 0.225± 0.033 | 0.222± 0.021 | 0.242 ± 0.147 | 0.653± 0.137 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(ICI040)

BATS 4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
 REPORT TYPE : A1
 SEX : MALE
 UNIT : g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 2

| Group Name | NO. of Animals | SPLEEN | LIVER | BRAIN |
|------------|-------------------|--------------|--------------|--------------|
| Control | 33 | 0.126± 0.113 | 1.879± 0.576 | 0.449± 0.014 |
| 512 ppm | 34 | 0.161± 0.325 | 1.857± 0.728 | 0.453± 0.019 |
| 1280 ppm | 36 | 0.168± 0.194 | 1.799± 0.687 | 0.451± 0.017 |
| 3200 ppm | 35 | 0.094± 0.054 | 1.782± 0.537 | 0.449± 0.019 |

Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL040)

BATS 4

TABLE J 2

ORGAN WEIGHT, ABSOLUTE: FEMALE

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:EDF1]
 REPORT TYPE : A1
 SEX : FEMALE
 UNIT : g

ORGAN WEIGHT-ABSOLUTE (SUMMARY)
 SURVIVAL ANIMALS (105W)

PAGE : 3

| Group Name | NO. of Animals | Body Weight | ADRENALS | OVARIES | HEART | LUNGS | KIDNEYS |
|------------|----------------|-------------|---------------|---------------|---------------|---------------|---------------|
| Control | 34 | 36.4 ± 5.3 | 0.014 ± 0.003 | 0.106 ± 0.211 | 0.170 ± 0.024 | 0.198 ± 0.042 | 0.558 ± 0.642 |
| 512 ppm | 28 | 35.9 ± 5.4 | 0.013 ± 0.001 | 0.055 ± 0.157 | 0.176 ± 0.031 | 0.189 ± 0.054 | 0.432 ± 0.057 |
| 1280 ppm | 28 | 37.4 ± 4.7 | 0.014 ± 0.002 | 0.057 ± 0.147 | 0.176 ± 0.025 | 0.181 ± 0.013 | 0.472 ± 0.225 |
| 3200 ppm | 30 | 35.1 ± 6.8 | 0.014 ± 0.004 | 0.067 ± 0.210 | 0.167 ± 0.020 | 0.224 ± 0.204 | 0.471 ± 0.153 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(ICL040)

BATS 4

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/CrJ[CrJ:DDF1]

REPORT TYPE : AI

SEX : FEMALE

UNIT : g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)

SURVIVAL ANIMALS (105W)

| Group Name | NO. of Animals | SPLEEN | LIVER | BRAIN |
|---|----------------|--------------|--------------|--------------|
| Control | 34 | 0.232± 0.307 | 1.404± 0.425 | 0.468± 0.019 |
| 512 ppm | 28 | 0.167± 0.188 | 1.403± 0.262 | 0.467± 0.013 |
| 1280 ppm | 28 | 0.138± 0.081 | 1.368± 0.235 | 0.467± 0.015 |
| 3200 ppm | 30 | 0.178± 0.247 | 1.412± 0.291 | 0.468± 0.013 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | |
| Test of Dunnett | | | | |
| (HCL040) | | | | BATS 4 |

TABLE K 1

ORGAN WEIGHT, RELATIVE: MALE

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/CrJ[Crj:EDF1]

REPORT TYPE : A1

SEX : MALE

UNIT : %

ORGAN WEIGHT-RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 1

| Group Name | NO. of Animals | Body Weight (g) | ADRENALS | TESTES | HEART | LUNGS | KIDNEYS |
|------------|----------------|-----------------|---------------|---------------|-----------------|---------------|----------------|
| Control | 33 | 45.5 ± 8.2 | 0.023 ± 0.006 | 0.507 ± 0.119 | 0.498 ± 0.097 | 0.473 ± 0.144 | 1.441 ± 0.385 |
| 512 ppm | 34 | 49.8 ± 7.1 | 0.020 ± 0.004 | 0.454 ± 0.080 | 0.441 ± 0.074** | 0.443 ± 0.203 | 1.330 ± 0.576* |
| 1280 ppm | 36 | 45.8 ± 8.8 | 0.024 ± 0.008 | 0.501 ± 0.115 | 0.498 ± 0.127 | 0.477 ± 0.151 | 1.660 ± 1.221 |
| 3200 ppm | 35 | 48.5 ± 7.2 | 0.030 ± 0.050 | 0.476 ± 0.108 | 0.468 ± 0.088 | 0.554 ± 0.601 | 1.392 ± 0.450 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$

Test of Dunnett

(HCL042)

BAIS 4

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/CrJ[Crlj:BDP1]

REPORT TYPE : A1

SEX : MALE

UNIT : %

ORGAN WEIGHT-RELATIVE (SUMMARY)
SURVIVAL ANIMALS (105W)

PAGE : 2

| Group Name | NO. of Animals | SPLEEN | LIVER | BRAIN |
|------------|-------------------|---------------|---------------|---------------|
| Control | 33 | 0.299 ± 0.279 | 4.323 ± 1.775 | 1.024 ± 0.223 |
| 512 ppm | 34 | 0.331 ± 0.688 | 3.883 ± 2.140 | 0.928 ± 0.140 |
| 1280 ppm | 36 | 0.391 ± 0.437 | 4.149 ± 2.229 | 1.025 ± 0.216 |
| 3200 ppm | 35 | 0.209 ± 0.147 | 3.878 ± 1.871 | 0.952 ± 0.182 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL042)

BATS 4

TABLE K 2

ORGAN WEIGHT, RELATIVE: FEMALE

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/CrJ[Crj:DDF1]

REPORT TYPE : A1

SEX : FEMALE

UNIT : %

ORGAN WEIGHT:RELATIVE (SUMMARY)

SURVIVAL ANIMALS (105W)

PAGE : 3

| Group Name | NO. of Animals | Body Weight (g) | ADRENALS | OVARIES | HEART | LUNGS | KIDNEYS |
|------------|----------------|-----------------|--------------|--------------|--------------|--------------|--------------|
| Control | 34 | 36.4± 6.3 | 0.038± 0.008 | 0.296± 0.607 | 0.477± 0.085 | 0.553± 0.101 | 1.505± 1.331 |
| 512 ppm | 28 | 35.9± 5.4 | 0.037± 0.007 | 0.163± 0.476 | 0.499± 0.111 | 0.548± 0.248 | 1.228± 0.227 |
| 1280 ppm | 28 | 37.4± 4.7 | 0.038± 0.007 | 0.151± 0.382 | 0.475± 0.075 | 0.491± 0.073 | 1.282± 0.669 |
| 3200 ppm | 30 | 35.1± 6.8 | 0.041± 0.016 | 0.211± 0.696 | 0.490± 0.100 | 0.752± 1.176 | 1.400± 0.598 |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Dunnett

(HCL042)

BATS 4

STUDY NO. : 0580

ANIMAL : MOUSE B6D2F1/CrJ[Crj:DDF1]

REPORT TYPE : AI

SEX : FEMALE

UNIT: %

ORGAN WEIGHT-RELATIVE (SUMMARY)

SURVIVAL ANIMALS (105W)

| Group Name | No. of Animals | SPLEEN | LIVER | BRAIN |
|---|----------------|--------------|--------------|--------------|
| Control | 34 | 0.625± 0.705 | 3.873± 0.929 | 1.325± 0.244 |
| 512 ppm | 28 | 0.506± 0.655 | 4.005± 1.022 | 1.333± 0.214 |
| 1280 ppm | 28 | 0.371± 0.214 | 3.665± 0.503 | 1.268± 0.182 |
| 3200 ppm | 30 | 0.487± 0.546 | 4.094± 0.831 | 1.391± 0.324 |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 | | | | |
| Test of Dunnett | | | | BATS 4 |
| (HCL042) | | | | |

TABLE L 1

HISTOPATHOLOGICAL FINDINGS:

NON-NEOPLASTIC LESIONS:MALE: ALL ANIMALS

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 1

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|----------------------------------|------------------------------|-------------------------|-------|-------|-------|---------|-------|-------|-------|---------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Integumentary system/appendage] | | | | | | | | | | | | | | | | | | | | | |
| skin/app | ulcer | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (2) | (0) | (0) | (0) | (2) | (0) | (0) |
| | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | |
| | squamous cell hyperplasia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) |
| | scab | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (0) | (0) |
| | epidermal cyst | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | duct ectasia:sebaceous gland | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | thrombus | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | |
| [Respiratory system] | | | | | | | | | | | | | | | | | | | | | |
| nasal cavit | mineralization | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (2) | (0) | (0) | (0) |
| | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(HPT150)

BA154

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BNF1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105#)

PAGE : 2

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|---|---|--|------------|--------------|--------------|---------------|------------|------------|--------------|---------------|--------------|------------|--------------|----------------|------------|------------|------------|----------------|--|--|--|
| | | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | | | | |
| [Respiratory system] | | | | | | | | | | | | | | | | | | | | | |
| nasal cavity | inflammation | 0 (0) | 1 (2) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 1 (2) | 0 (0) | <50> | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | |
| | | eosinophilic change:olfactory epithelium | | | | | | | | | | | | | | | | | | | |
| | 30 (60) | 2 (4) | 1 (2) | 0 (0) | 27 (54) | 7 (14) | 0 (0) | 0 (0) | 0 (0) | 27 (54) | 10 (20) | 0 (0) | 0 (0) | 26 (52) | 2 (4) | 0 (0) | 0 (0) | | | | |
| | eosinophilic change:respiratory epithelium | | | | | | | | | | | | | | | | | | | | |
| | 12 (24) | 14 (28) | 1 (2) | 0 (0) | 30 (60) | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 25 (50) | 6 (12) | 0 (0) | 0 (0) | 14 (28) | 1 (2) | 0 (0) | 0 (0) | | | | |
| | inflammation:respiratory epithelium | | | | | | | | | | | | | | | | | | | | |
| | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | | |
| | respiratory metaplasia:olfactory epithelium | | | | | | | | | | | | | | | | | | | | |
| | 23 (46) | 3 (6) | 0 (0) | 0 (0) | 27 (54) | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 17 (34) | 4 (8) | 0 (0) | 0 (0) | 18 (36) | 1 (2) | 0 (0) | 0 (0) | | | | |
| | respiratory metaplasia:gland | | | | | | | | | | | | | | | | | | | | |
| 21 (42) | 8 (16) | 3 (6) | 0 (0) | 28 (56) | 14 (28) | 0 (0) | 0 (0) | 0 (0) | 20 (40) | 16 (32) | 0 (0) | 0 (0) | 26 (52) | 6 (12) | 0 (0) | 0 (0) | | | | | |
| squamous cell metaplasia:respiratory epithelium | | | | | | | | | | | | | | | | | | | | | |
| 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | | | | |
| epithelial hyperplasia:transitional cell type | | | | | | | | | | | | | | | | | | | | | |
| 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BA1S4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 3

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--|--|-------------------------|-------|-------|-------|------------|-----|-----|-----|------------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Respiratory system] | | | | | | | | | | | | | | | | | | | | | |
| nasal cavity | necrosis:olfactory epithelium | 0 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| nasopharynx | eosinophilic change | 1 | 0 | 1 | 0 | <50> | | | | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (2) | (0) | | | | | (2) | (0) | (0) | (0) | (6) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | inflammation | 1 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| lung | hemorrhage | 1 | 0 | 0 | 0 | <50> | | | | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | edema | 1 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | inflammatory infiltration | 1 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (2) | (2) | (0) | (0) | (2) | (0) | (0) | (0) |
| | lymphocytic infiltration | 2 | 0 | 0 | 0 | | | | | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | | | | | (4) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| (UPT150) | | | | | | | | | | | | | | | | | | | | | |
| BAIS4 | | | | | | | | | | | | | | | | | | | | | |

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr1J[Crj:BDPL]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 4

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--|-----------------------------|---------------------------------------|-----|-----|-----|---------------|-----|-----|-----|---------------|------|------|-----|----------------|-----|------|------|----------------|-----|-----|--|
| | | Grade | | | | 1 | | | | 1 | | | | 1 | | | | 1 | | | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| lung | accumulation of foamy cells | 5 | 0 | 0 | 0 | <50> | 2 | 0 | 0 | 0 | <50> | 5 | 0 | 0 | 0 | <50> | 7 | 0 | 0 | 0 | |
| | | (10) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (10) | (0) | (0) | (0) | (0) | (14) | (0) | (0) | (0) | |
| | | bronchiolar-alveolar cell hyperplasia | | | | | | | | | | | | | | | | | | | |
| | | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | | |
| | | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (2) | (0) | (0) | (0) | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| bone marrow | mastcell hyperplasia | 0 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| | | myelofibrosis | | | | | | | | | | | | | | | | | | | |
| | | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | | |
| | | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | | |
| granulopoiesis:increased | | | | | | | | | | | | | | | | | | | | | |
| | | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | | |
| | | (4) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (6) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| lymph node | inflammatory infiltration | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| | | Grade | | | | | | | | | | | | | | | | | | | |
| < a > | | | | | | | | | | | | | | | | | | | | | |
| b | | | | | | | | | | | | | | | | | | | | | |
| (c) | | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | | | | | | | | | |
| BALSA | | | | | | | | | | | | | | | | | | | | | |

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
 REPORT TYPE : AI
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 5

| Organ | Findings | Group Name No. of Animals on Study | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|------------------------|------------------------------|---------------------------------------|--------------|-------------|------------|---------|--------------|-------------|------------|---------|--------------|-------------|-------------|------------|------------|------------|------------|--------------|--------------|-------------|------------|
| | | Grade | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| spleen | atrophy | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | congestion | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | angiectasis | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | deposit of hemosiderin | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| | deposit of melanin | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 2 (4) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| | extramedullary hematopoiesis | 10 (20) | 13 (26) | 6 (12) | 0 (0) | <50> | 19 (38) | 9 (18) | 2 (4) | <50> | 12 (24) | 9 (18) | 6 (12) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 16 (32) | 11 (22) | 5 (10) | 0 (0) |
| | follicular hyperplasia | 1 (2) | 1 (2) | 1 (2) | 0 (0) | <50> | 3 (6) | 0 (0) | 0 (0) | <50> | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 1 (2) | 0 (0) | 0 (0) |
| {Circulatory system} | | | | | | | | | | | | | | | | | | | | | |
| heart | mineralization | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 2 (4) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(HPT150)

BAIS4

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BNF1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 6

| Organ | Findings | Group Name | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--|--|-------------------------|------------|------------|------------|------------|------------|------------|------------|-------------|------------|------------|------------|------------|------------|------------|------------|
| | | No. of Animals on Study | | | | Control | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| {Circulatory system} | | | | | | | | | | | | | | | | | |
| heart | inflammatory infiltration | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | scar | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | myocarditis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | arteritis | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| {Digestive system} | | | | | | | | | | | | | | | | | |
| oral cavity | ulcer | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| tooth | dysplasia | 3 (6) | 1 (2) | 0 (0) | 0 (0) | 3 (6) | 2 (4) | 0 (0) | 0 (0) | 7 (14) | 3 (6) | 0 (0) | 0 (0) | 2 (4) | 3 (6) | 0 (0) | 0 (0) |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | BA154 |

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 7

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--------------------|--------------------------|-------------------------|-------|-------|-------|---------|-------|-------|-------|---------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Digestive system) | | | | | | | | | | | | | | | | | | | | | |
| tooth | odontogenic cyst | | | | | | | | | | | | | | | | | | | | |
| | | 0 | 0 | 1 | 0 | <50> | | | | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| tongue | arteritis | | | | | | | | | | | | | | | | | | | | |
| | | 1 | 0 | 0 | 0 | <50> | | | | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| salivary gl | atrophy:focal | | | | | | | | | | | | | | | | | | | | |
| | | 0 | 0 | 0 | 0 | <50> | | | | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | lymphocytic infiltration | | | | | | | | | | | | | | | | | | | | |
| | | 1 | 0 | 0 | 0 | | | | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | granulation | | | | | | | | | | | | | | | | | | | | |
| | | 0 | 0 | 0 | 0 | | | | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (2) | (0) | (0) |
| | xanthogranuloma | | | | | | | | | | | | | | | | | | | | |
| | | 0 | 0 | 0 | 0 | | | | | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (2) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| stomach | ulcer:forestomach | | | | | | | | | | | | | | | | | | | | |
| | | 1 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 3 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (2) | (0) | (6) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BA1S4

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crj:DOF1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 8

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--|--------------------------------|-------------------------|------------|------------|------------|--------------|------------|------------|------------|--------------|------------|------------|------------|--------------|------------|------------|------------|-------------|------------|------------|------------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Digestive system] | | | | | | | | | | | | | | | | | | | | | |
| stomach | hyperplasia:forestomach | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 1 (2) | 0 (0) | 0 (0) |
| | erosion:glandular stomach | 5 (10) | 0 (0) | 0 (0) | 0 (0) | 4 (8) | 1 (2) | 0 (0) | 0 (0) | 4 (8) | 1 (2) | 0 (0) | 0 (0) | 4 (8) | 1 (2) | 0 (0) | 0 (0) | 3 (6) | 0 (0) | 0 (0) | 0 (0) |
| | ulcer:glandular stomach | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | hyperplasia:glandular stomach | 15 (30) | 0 (0) | 0 (0) | 0 (0) | 13 (26) | 0 (0) | 0 (0) | 0 (0) | 13 (26) | 0 (0) | 0 (0) | 0 (0) | 10 (20) | 0 (0) | 0 (0) | 0 (0) | 7 (14) | 0 (0) | 0 (0) | 0 (0) |
| | degeneration:glandular stomach | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| large intes | inflammation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| liver | angiectasis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | | | | | | | | | |
| a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | | |
| b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | | |
| c : b / a * 100 | | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| (IPT150) | | | | | | | | | | | | | | | | | | | | | |

BALIS4

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BUF1]
REPORT TYPE : AI
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 9

| Organ | Findings | Group Name | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--------------------|---------------------------|-------------------------|-------|-------|-------|---------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | Control | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Digestive system] | | | | | | | | | | | | | | | | | |
| liver | necrosis:focal | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) |
| | fatty change:central | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| | inflammatory infiltration | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | granulation | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (2) | (0) | (0) |
| | inflammatory cell nest | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 5 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| | | (10) | (0) | (0) | (0) | (6) | (0) | (0) | (0) | (8) | (0) | (0) | (0) | (4) | (0) | (0) | (0) |
| | clear cell focus | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 1 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (2) | (0) | (6) | (0) | (0) | (2) | (0) | (0) | (4) | (2) | (0) | (0) |
| | acidophilic cell focus | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 2 | 2 | 1 | 0 | 1 | 3 | 0 | 0 | 2 | 1 | 1 | 0 | 4 | 0 | 1 | 0 |
| | | (4) | (4) | (2) | (0) | (2) | (6) | (0) | (0) | (4) | (2) | (2) | (0) | (8) | (0) | (2) | (0) |
| | basophilic cell focus | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (2) | (0) | (0) | (0) | (0) | (2) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(IPT150)

BAIS4

| Organ | Findings | Group Name | | | | | | | | | | | |
|--|------------------------|-------------------------|-------|-------|-------|---------|-------|-------|-------|---------|-------|-------|-------|
| | | No. of Animals on Study | | | | Control | | | | 512 ppm | | | |
| | | Grade | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| {Digestive system} | | | | | | | | | | | | | |
| liver | biliary cyst | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) |
| pancreas | islet cell hyperplasia | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 0 | 0 | 0 |
| | | (8) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (14) | (0) | (0) | (0) |
| {Urinary system} | | | | | | | | | | | | | |
| kidney | atrophy | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | cyst | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | hyaline droplet | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | deposit of hemosiderin | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | |
| a : Number of animals examined at the site | | | | | | | | | | | | | |
| b : Number of animals with lesion | | | | | | | | | | | | | |
| c : b / a * 100 | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | |
| BALSA | | | | | | | | | | | | | |

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BNF1]
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 11

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1250 ppm 50 | | | | 3200 ppm 50 | | | |
|------------------|------------------------------|---------------------------------------|-------|-------|-------|---------------|-------|-------|-------|---------------|-------|-------|-------|----------------|-------|-------|-------|----------------|-------|-------|-------|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Urinary system) | | | | | | | | | | | | | | | | | | | | | |
| kidney | lymphocytic infiltration | | | | | | | | | | | | | | | | | | | | |
| | | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (6) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | |
| | scar | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | inflammatory polyp | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (2) | (2) | (0) | (0) | (2) | (2) | (0) | (0) | (2) | (2) | (0) | (0) | (0) | (0) | (0) |
| | ossification | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | hydronephrosis | 2 | 0 | 3 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 2 | 0 | 1 | 1 | 2 | 0 | 0 | 1 | 2 | 0 |
| | | (4) | (0) | (6) | (0) | (2) | (0) | (4) | (0) | (2) | (0) | (4) | (0) | (2) | (2) | (4) | (0) | (0) | (2) | (4) | (0) |
| | papillary necrosis | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | mineralization:cortex | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | regeneration:proximal tubule | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BALS4

| Organ | Findings | Group Name | | | | | | | | | | | |
|--|---------------------------|-------------------------|-------|-------|-------|---------|-------|-------|-------|---------|-------|-------|-------|
| | | No. of Animals on Study | | | | Control | | | | 512 ppm | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| {Urinary system} | | | | | | | | | | | | | |
| urin bladd | dilatation | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 1 | 3 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 4 | 0 |
| | | (0) | (2) | (6) | (0) | (0) | (0) | (2) | (0) | (2) | (2) | (8) | (0) |
| | inflammation | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| urethra | inflammation | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| {Endocrine system} | | | | | | | | | | | | | |
| pituitary | cyst | <49> | | | | <49> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | inflammatory infiltration | <49> | | | | <49> | | | | <50> | | | |
| | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | hyperplasia | <49> | | | | <49> | | | | <50> | | | |
| | | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (6) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | |
| < a > a : Number of animals examined at the site | | | | | | | | | | | | | |
| b b : Number of animals with lesion | | | | | | | | | | | | | |
| (c) c : b / a * 100 | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | |

BALS4

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrLj[Crj:BDP1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

PAGE : 13

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--------------------|-----------------------------------|---------------------------------------|-------|-------|-------|---------------|-------|-------|-------|---------------|-------|-------|-------|----------------|-------|-------|-------|----------------|-------|-------|-------|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Endocrine system) | | | | | | | | | | | | | | | | | | | | | |
| pituitary | Rathke pouch | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (8) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| thyroid | cyst | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (8) | (0) | (0) | (0) | (6) | (0) | (0) | (0) |
| | focal follicular cell hyperplasia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| parathyroid | cyst | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| adrenal | spindle-cell hyperplasia | 28 | 4 | 0 | 0 | 21 | 2 | 0 | 0 | 21 | 2 | 0 | 0 | 21 | 1 | 0 | 0 | 16 | 4 | 0 | 0 * |
| | | (56) | (8) | (0) | (0) | (42) | (4) | (0) | (0) | (43) | (2) | (0) | (0) | (43) | (2) | (0) | (0) | (32) | (8) | (0) | (0) |
| | hyperplasia:cortical cell | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | hyperplasia:medulla | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BALIS4

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
ALL ANIMALS (0-105W)

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/Cr-I.[Cr.j:EDF1]
REPORT TYPE : A1
SEX : MALE

[illegible]

| Grade | 1 : Slight | 2 : Moderate | 3 : Marked | 4 : Severe |
|-------|--|--------------|------------|------------|
| < a > | a : Number of animals examined at the site | | | |
| b | b : Number of animals with lesion | | | |
| (c) | c : b / a * 100 | | | |

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(11PT150)

BAIS4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr-Li[Cr-i: BDF-1]
 REPORT TYPE : AI
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 15

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--|----------------|---------------------------------------|----------|----------|----------|---------------|----------|----------|----------|---------------|----------|----------|----------|----------------|----------|----------|----------|----------------|--|--|--|
| | | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | | | | |
| {Reproductive system} | | | | | | | | | | | | | | | | | | | | | |
| mammary gl | duct ectasia | 0 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | | | |
| | | (0) | (0) | (0) | (0) | | (2) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | | |
| {Nervous system} | | | | | | | | | | | | | | | | | | | | | |
| brain | mineralization | 12 | 0 | 0 | 0 | <50> | 9 | 0 | 0 | 0 | <50> | 6 | 0 | 0 | 0 | <50> | 12 | 0 | | | |
| | | (24) | (0) | (0) | (0) | | (18) | (0) | (0) | (0) | | (12) | (0) | (0) | (0) | | (24) | (0) | | | |
| {Special sense organs/appendage} | | | | | | | | | | | | | | | | | | | | | |
| eye | keratitis | 0 | 0 | 1 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 1 | 0 | | | |
| | | (0) | (0) | (2) | (0) | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (2) | (0) | | | |
| Harder gl | hyperplasia | 1 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 | <50> | 0 | 1 | | | |
| | | (2) | (0) | (0) | (0) | | (2) | (0) | (0) | (0) | | (2) | (0) | (0) | (0) | | (0) | (2) | | | |
| {Musculoskeletal system} | | | | | | | | | | | | | | | | | | | | | |
| bone | osteosclerosis | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 1 | 0 | | | |
| | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (2) | (0) | | | |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | | | | | | | | | |
| a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | | |
| b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | | |
| c : b / a * 100 | | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |

(HPT150)

BAIS4

STUDY NO. : 0580
 ANIMAL : MOUSE B6DZF1/Cr-Li[Cr]-BDF1
 REPORT TYPE : A1
 SEX : MALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 16

| Organ | Findings | Group Name | | | | | | | | | | | |
|--|---------------------------|-------------------------|------------|------------|------------|---------|-----|------|-----|------------|------------|------------|------------|
| | | No. of Animals on Study | | | | Control | | | | 512 ppm | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| {Body cavities} | | | | | | | | | | | | | |
| pleura | inflammatory infiltration | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | | <50> | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | | | | | | | | <50> | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| peritoneum | peritonitis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | | <50> | | 0 (0) | 0 (0) | 1 (2) | 0 (0) |
| | | | | | | | | <50> | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| mesenterium | hemorrhage | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | | <50> | | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| | | | | | | | | <50> | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | |
| a : Number of animals examined at the site | | | | | | | | | | | | | |
| b : Number of animals with lesion | | | | | | | | | | | | | |
| c : b / a * 100 | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | |

(HPT150)

BA1S4

TABLE L 4

HISTOPATHOLOGICAL FINDINGS: NON-NEOPLASTIC
LESIONS: FEMALE: ALL ANIMALS

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrLi[Crj:BUF1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 17

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | | | | | |
|--|----------------|---------------------------------------|------------|------------|------------|---------------|------------|------------|------------|---------------|------------|------------|------------|----------------|------------|------------|------------|----------------|------------|------------|------------|------------|------------|------------|--|
| | | 1 | | 2 | | 3 | | 4 | | 1 | | 2 | | 3 | | 4 | | 1 | | 2 | | 3 | | 4 | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | |
| {Integumentary system/appandage} | | | | | | | | | | | | | | | | | | | | | | | | | |
| skin/app | ulcer | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| | inflammation | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| | scab | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| | epidermal cyst | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | | | | | |
| nasal cavit | mineralization | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| | inflammation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| eosinophilic change:olfactory epithelium | | | | | | | | | | | | | | | | | | | | | | | | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(UPT150)

BA154

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--|---|---------------------------------------|------------|----------|----------|---------------|------------|------------|----------|---------------|----------|------|------------|----------------|----------|----------|------|----------------|------------|----------|----------|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Respiratory system] | | | | | | | | | | | | | | | | | | | | | |
| nasal cavity | | | | | | | | | | | | | | | | | | | | | |
| | eosinophilic change:respiratory epithelium | 19 (38) | 24 (48) | 0 (0) | 0 (0) | <50> | 16 (32) | 16 (32) | 4 (8) | 0 (0) | 0 (0) | <50> | 19 (38) | 17 (34) | 3 (6) | 0 (0) | <50> | 18 (36) | 13 (26) | 1 (2) | 0 (0) |
| | respiratory metaplasia:olfactory epithelium | 13 (26) | 2 (4) | 0 (0) | 0 (0) | | 10 (20) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 8 (16) | 1 (2) | 0 (0) | 0 (0) | | 13 (26) | 1 (2) | 0 (0) | 0 (0) |
| | respiratory metaplasia:gland | 35 (70) | 9 (18) | 0 (0) | 0 (0) | | 34 (68) | 9 (18) | 0 (0) | 0 (0) | 0 (0) | | 40 (80) | 5 (10) | 0 (0) | 0 (0) | | 36 (72) | 5 (10) | 0 (0) | 0 (0) |
| | squamous cell metaplasia:respiratory epithelium | 2 (4) | 0 (0) | 0 (0) | 0 (0) | | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | ulcer:respiratory epithelium | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| nasopharynx | | | | | | | | | | | | | | | | | | | | | |
| | eosinophilic change | 3 (6) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 2 (4) | 0 (0) | 0 (0) | 0 (0) | <50> | 3 (6) | 0 (0) | 0 (0) | 0 (0) |
| lung | | | | | | | | | | | | | | | | | | | | | |
| | lymphocytic infiltration | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) |
| Grade | | | | | | | | | | | | | | | | | | | | | |
| < a > | | | | | | | | | | | | | | | | | | | | | |
| b | | | | | | | | | | | | | | | | | | | | | |
| (c) | | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| (0/7/150) | | | | | | | | | | | | | | | | | | | | | |
| BALS4 | | | | | | | | | | | | | | | | | | | | | |

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
 REPORT TYPE : AI
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 19

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|-------------------------|---------------------------------------|---------------------------------------|----------|----------|----------|---------------|----------|----------|----------|---------------|----------|----------|----------|----------------|----------|----------|----------|----------------|----------|----------|----------|
| | | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| lung | accumulation of foamy cells | 7 (14) | 0 (0) | 0 (0) | 0 (0) | 12 (24) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (8) | 0 (0) | 0 (0) | 0 (0) | 10 (20) | 0 (0) | 0 (0) | 0 (0) |
| | | <50> | | | | | | | | | | | | | | | | | | | |
| bone | bronchiolar-alveolar cell hyperplasia | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | | <50> | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| bone marrow | angiectasis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| | | <50> | | | | | | | | | | | | | | | | | | | |
| granulation | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | |
| | <50> | | | | | | | | | | | | | | | | | | | | |
| increased hematopoiesis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | |
| | <50> | | | | | | | | | | | | | | | | | | | | |
| myelofibrosis | 1 (2) | 1 (2) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |
| | <50> | | | | | | | | | | | | | | | | | | | | |
| spleen | deposit of hemosiderin | 5 (10) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 4 (8) | 0 (0) | 0 (0) | 0 (0) | 11 (22) | 0 (0) | 0 (0) | 0 (0) |
| | | <50> | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | |
| {Respiratory system} | | | | | | | | | | | | | | | | | | | | | |
| {Hematopoiet | | | | | | | | | | | | | | | | | | | | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b : Number of animals with lesion
 (c) c : b / a * 100

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(HPT150)

BA1S4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BNF1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 20

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | | |
|--|--|---------------------------------------|------------|------------|-------|---------------|-------|-------|-------|---------------|-------|-------|-------|----------------|-------|-------|-------|----------------|--------|-------|-------|-------|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | | | | | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | | | | | |
| {Hematopoietic system} | | | | | | | | | | | | | | | | | | | | | | |
| spleen | deposit of melanin | 1 | 0 | 0 | 0 | <50> | <50> | <50> | <50> | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | 7 | 5 | 2 | 0 | 11 | 2 | 0 | 0 | 14 | 3 | 6 | 0 | 13 | 6 | 3 | 0 | (26) | (12) | (6) | (0) | (0) |
| extramedullary hematopoiesis | | | | | | | | | | | | | | | | | | | | | | |
| | follicular hyperplasia | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | <50> | 0 | 0 | 1 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (6) | (0) | (0) | (2) | (2) | (2) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (2) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | | |
| {Circulatory system} | | | | | | | | | | | | | | | | | | | | | | |
| heart | thrombus | 0 | 1 | 0 | 0 | <50> | <50> | <50> | <50> | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | <50> | 0 | 1 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | | |
| | mineralization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | | |
| | inflammatory infiltration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | | |
| | arteritis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | <50> | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) |
| | | | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | | |
| Grade | 1 : Slight | 2 : Moderate | 3 : Marked | 4 : Severe | | | | | | | | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | | |

(IPT150)

BALS4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:DOF1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 21

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--------------------|---------------------------|-------------------------|-------|-------|-------|---------|-----|-----|-----|---------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Digestive system] | | | | | | | | | | | | | | | | | | | | | |
| oral cavity | | | | | | | | | | | | | | | | | | | | | |
| | thrombus | 0 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) |
| tooth | | | | | | | | | | | | | | | | | | | | | |
| | dysplasia | 2 | 0 | 0 | 0 | <50> | | | | 0 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | | | | | (0) | (4) | (0) | (0) | (6) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| tongue | | | | | | | | | | | | | | | | | | | | | |
| | inflammation | 0 | 0 | 0 | 0 | <50> | | | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| salivary gl | | | | | | | | | | | | | | | | | | | | | |
| | lymphocytic infiltration | 4 | 0 | 0 | 0 | <50> | | | | 3 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 4 | 0 | 0 | 0 |
| | | (8) | (0) | (0) | (0) | | | | | (6) | (0) | (0) | (0) | (8) | (0) | (0) | (0) | (8) | (0) | (0) | (0) |
| stomach | | | | | | | | | | | | | | | | | | | | | |
| | ulcer:forestomach | 2 | 0 | 0 | 0 | <50> | | | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | hyperplasia:forestomach | 2 | 1 | 0 | 0 | | | | | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| | | (4) | (2) | (0) | (0) | | | | | (6) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) |
| | erosion:glandular stomach | 3 | 1 | 0 | 0 | | | | | 8 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| | | (6) | (2) | (0) | (0) | | | | | (16) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (6) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100

Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(IPT150)

BA154

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
REPORT TYPE : A1
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 22

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--|--|---------------------------------------|------------|------------|------------|---------------|------------|------------|------------|---------------|------------|------------|------------|----------------|------------|------------|------------|----------------|------------|--|--|
| | | Grade | | | | 1 | | | | 2 | | | | 3 | | | | 4 | | | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | | |
| (Digestive system) | | | | | | | | | | | | | | | | | | | | | |
| stomach | ulcer:glandular stomach | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | |
| | hyperplasia:glandular stomach | 13 (26) | | | | 0 (12) | | | | 6 (12) | | | | 4 (8) | | | | 0 (0) * | | | |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| small intes | lymphocytic infiltration | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | |
| liver | angiectasis | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | | |
| | necrosis:central | 1 (2) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| | necrosis:focal | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| | inflammatory infiltration | 1 (2) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | | 0 (0) | | | |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | | |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | |
| Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| (IPT150) | | | | | | | | | | | | | | | | | | | | | |
| BA154 | | | | | | | | | | | | | | | | | | | | | |

BALS4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crl:BR1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 23

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|--------------------|------------------------------|---------------------------------------|-----------|-----------|-----------|---------------|-----------|-----------|-----------|---------------|-----------|-----------|-----------|----------------|-----------|-----------|-----------|----------------|-----|-----|-----|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Digestive system) | | | | | | | | | | | | | | | | | | | | | |
| liver | Lymphocytic infiltration | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | granulation | 11 (22) | 1 (2) | 0 (0) | 0 (0) | 16 (32) | 1 (2) | 0 (0) | 0 (0) | 20 (40) | 1 (2) | 0 (0) | 0 (0) | 17 (34) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | | |
| | inflammatory cell nest | 4 (8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | |
| | extramedullary hematopoiesis | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 3 (6) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | |
| | clear cell focus | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | | |
| | acidophilic cell focus | 1 (2) | 1 (2) | 2 (4) | 0 (0) | 1 (2) | 1 (2) | 4 (8) | 0 (0) | 1 (2) | 2 (4) | 3 (6) | 0 (0) | 1 (2) | 1 (2) | 2 (4) | 0 (0) | | | | |
| | basophilic cell focus | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 2 (4) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | | | |
| | biliary cyst | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100

Significant difference ; * : $P \leq 0.05$ ** : $P \leq 0.01$ Test of Chi Square

(IPT150)

BA154

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
 REPORT TYPE : AI
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY)
 ALL ANIMALS (0-105W)

PAGE : 24

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1250 ppm | | | | 3200 ppm | | | |
|---|--------------------------|---|-------|-------|-------|---------|-------|-------|-------|---------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Digestive system) | | | | | | | | | | | | | | | | | | | | | |
| liver | mineralization:central | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| gall bladd | hyperplasia | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | |
| pancreas | lymphocytic infiltration | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) |
| kidney | cyst | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) |
| (Urinary system) | | | | | | | | | | | | | | | | | | | | | |
| Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe | | | | | | | | | | | | | | | | | | | | | |
| < a > | | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | |
| b | | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | |
| (c) | | c : b / a * 100 | | | | | | | | | | | | | | | | | | | |
| Significant difference ; | | * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | |
| (IPT150) | | | | | | | | | | | | | | | | | | | | | |

BA154

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/Cr1j[Crj:BDFl]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 25

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | |
|------------------|---------------------------|---------------------------------------|-------|-------|-------|---------------|--------|-------|-------|---------------|-------|-------|-------|----------------|--------|--------|--------|----------------|--------|--------|-------|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| (Urinary system) | | | | | | | | | | | | | | | | | | | | | |
| kidney | hyaline droplet | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 3 | 3 | 1 | 0 | 1 | 6 | 0 | 0 | 4 | 4 | 2 | 0 | 4 | 8 | 4 | 0 | 3 | 7 | 5 | 0 |
| | | (6) | (6) | (2) | (0) | (2) | (12) | (0) | (0) | (8) | (8) | (4) | (0) | (0) | (14) | (10) | (0) | (6) | (14) | (10) | (0) |
| | deposit of amyloid | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | inflammatory infiltration | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | lymphocytic infiltration | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 8 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 10 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| | | (16) | (4) | (0) | (0) | (6) | (0) | (0) | (0) | (10) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (6) | (0) | (0) | (0) |
| | scar | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | inflammatory polyp | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 1 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 2 | 0 | 0 |
| | | (2) | (4) | (0) | (0) | (4) | (2) | (0) | (0) | (2) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) |
| | ossification | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | hydronephrosis | <50> | | | | <50> | | | | <50> | | | | <50> | | | | <50> | | | |
| | | 0 | 2 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 5 | 0 |
| | | (0) | (4) | (4) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (2) | (10) | (0) | (2) | (10) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
 < a > a : Number of animals examined at the site
 b b : Number of animals with lesion
 (c) c : b / a * 100
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(UPT150)

BA1S4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BNF1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 26

| Organ | Findings | Group Name No. of Animals on Study Grade | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | | | | | | |
|--|--|--|----------|----------|----------|---------------|----------|----------|----------|---------------|----------|----------|----------|----------------|----------|----------|----------|----------------|-------|-------|-------|-------|-------|-------|-------|---|
| | | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | 1 (%) | 2 (%) | 3 (%) | 4 (%) | | | | | | | | | |
| {Urinary system} | | | | | | | | | | | | | | | | | | | | | | | | | | |
| kidney | regeneration:proximal tubule | 0 | 0 | 0 | 0 | <50> | | | | <50> | | | | 0 | 0 | 0 | 0 | <50> | | | | | 0 | 0 | 1 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | |
| urin bladd | dilatation | 1 | 1 | 0 | 0 | <50> | | | | <50> | | | | 1 | 0 | 0 | 0 | <50> | | | | | 0 | 0 | 0 | 0 |
| | | (2) | (2) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| | inflammatory infiltration | 1 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| | lymphocytic infiltration | 0 | 0 | 0 | 0 | | | | | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| {Endocrine system} | | | | | | | | | | | | | | | | | | | | | | | | | | |
| pituitary | angiectasis | 0 | 0 | 0 | 0 | <50> | | | | <50> | | | | 1 | 0 | 0 | 0 | <50> | | | | | 1 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | |
| | cyst | 0 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | | | | | | | | | | | | | | |
| BALSA | | | | | | | | | | | | | | | | | | | | | | | | | | |

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crj: BDF1]
REPORT TYPE : A1
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 27

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--------------------|------------------------------|---------------------------------------|------|-----|-----|---------------|-----|-----|-----|---------|------|-----|-----|----------|-----|-----|-----|----------|------|-----|-----|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Endocrine system] | | | | | | | | | | | | | | | | | | | | | |
| pituitary | hyperplasia | 9 | 5 | 3 | 0 | <50> | | | | 11 | 5 | 1 | 0 | 8 | 4 | 4 | 0 | 7 | 6 | 4 | 0 |
| | | (18) | (10) | (6) | (0) | | | | | (22) | (10) | (2) | (0) | (16) | (8) | (8) | (0) | (14) | (12) | (8) | (0) |
| | Ratlike pouch | 1 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| thyroid | cyst | 2 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| | | (4) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (6) | (0) | (0) | (0) |
| | Lymphocytic infiltration | 0 | 0 | 0 | 0 | | | | | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| parathyroid | cyst | 0 | 0 | 0 | 0 | <50> | | | | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (2) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| adrenal | fatty change | 0 | 0 | 1 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (2) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |
| | extramedullary hematopoiesis | 0 | 0 | 0 | 0 | | | | | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | (0) | (0) | (0) | (0) |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(UPT150)

BAIS4

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crl:BDP1]
REPORT TYPE : AI
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS :NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 28

| Organ | Findings | Group Name No. of Animals on Study | | | | Control 50 | | | | 512 ppm 50 | | | | 1280 ppm 50 | | | | 3200 ppm 50 | | | | |
|--------------------|--------------------------|---------------------------------------|-------------|-----------|-----------|---------------|-------------|-------------|-----------|---------------|------|-------------|-------------|----------------|-----------|------|-------------|----------------|-----------|-----------|-----|-----|
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Endocrine system] | | | | | | | | | | | | | | | | | | | | | | |
| adrenal | spindle-cell hyperplasia | 34 (68) | 13 (26) | 0 (0) | 0 (0) | <50> | 35 (70) | 11 (22) | 0 (0) | 0 (0) | <50> | 37 (74) | 10 (20) | 0 (0) | 0 (0) | <50> | 40 (80) | 9 (18) | 0 (0) | 0 (0) | | |
| | | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | |
| | | hyperplasia:cortical cell | | | | | | | | | | | | | | | | | | | | |
| | | focal fatty change:cortex | | | | | | | | | | | | | | | | | | | | |
| | angiectasis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 1 (2) | 0 (0) | 0 (0) | 0 (0) | | |
| | | 0 (0) | 0 (0) | 1 (2) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 1 (2) | 0 (0) | | |
| | | thrombus | | | | | | | | | | | | | | | | | | | | |
| | | cyst | | | | | | | | | | | | | | | | | | | | |
| | lymphocytic infiltration | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 1 (2) | 0 (0) | <50> | 3 (6) | 0 (0) | 2 (4) | 0 (0) | <50> | 0 (0) | 0 (0) | 1 (2) | 0 (0) | | |
| | | 1 (2) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | <50> | 0 (0) | 0 (0) | 0 (0) | 0 (0) | | |
| | | lymphocytic infiltration | | | | | | | | | | | | | | | | | | | | |

Grade 1 : Slight 2 : Moderate 3 : Marked 4 : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square

(UPT150)

BAISA

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
 REPORT TYPE : AI
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 29

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1280 ppm | | | | 3200 ppm | | | |
|--|--|-------------------------|-------|-------|-------|------------|--------|-------|-------|------------|------|--------|-------|----------|-------|------|--------|----------|-------|-------|------|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) |
| [Reproductive system] | | | | | | | | | | | | | | | | | | | | | |
| uterus | stromal hyperplasia | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> |
| | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | |
| | cystic endometrial hyperplasia | 28 | 0 | 0 | 0 | | 32 | 1 | 0 | 0 | | 29 | 0 | 0 | 0 | | 29 | 0 | 0 | 0 | |
| | | (56) | (0) | (0) | (0) | | (64) | (2) | (0) | (0) | | (58) | (0) | (0) | (0) | | (58) | (0) | (0) | (0) | |
| [Nervous system] | | | | | | | | | | | | | | | | | | | | | |
| brain | mineralization | 5 | 0 | 0 | 0 | <50> | 10 | 0 | 0 | 0 | <50> | 3 | 0 | 0 | 0 | <50> | 4 | 0 | 0 | 0 | |
| | | (10) | (0) | (0) | (0) | | (20) | (0) | (0) | (0) | | (6) | (0) | (0) | (0) | | (8) | (0) | (0) | (0) | |
| [Special sense organs/appendage] | | | | | | | | | | | | | | | | | | | | | |
| eye | keratitis | 2 | 0 | 0 | 0 | <50> | 0 | 1 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | <50> | 0 | 0 | 0 | 0 | |
| | | (4) | (0) | (0) | (0) | | (0) | (2) | (0) | (0) | | (0) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | |
| | degeneration:cornea | 0 | 1 | 0 | 0 | | 2 | 0 | 0 | 0 | | 0 | 0 | 0 | 0 | | 1 | 0 | 0 | 0 | |
| | | (0) | (2) | (0) | (0) | | (4) | (0) | (0) | (0) | | (0) | (0) | (0) | (0) | | (2) | (0) | (0) | (0) | |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | |
| Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01 Test of Chi Square | | | | | | | | | | | | | | | | | | | | | |
| [HPT150] | | | | | | | | | | | | | | | | | | | | | |
| BAIS4 | | | | | | | | | | | | | | | | | | | | | |

(HPT150)

BALS4

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[CrJ:EDF1]
 REPORT TYPE : A1
 SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : NON-NEOPLASTIC LESIONS (SUMMARY) ALL ANIMALS (0-105W)

PAGE : 30

| Organ | Findings | Group Name | | | | Control | | | | 512 ppm | | | | 1250 ppm | | | | 3200 ppm | | | | |
|----------------------------------|--|-------------------------|-------|-------|-------|---------------|-----|-----|-----|--------------------|-------|-------|-------|----------|-------|-------|-------|----------|-------|-------|-------|--|
| | | No. of Animals on Study | | | | 50 | | | | 50 | | | | 50 | | | | 50 | | | | |
| | | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | | | | | |
| | | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | (%) | | |
| {Special sense organs/appendage} | | | | | | | | | | | | | | | | | | | | | | |
| eye | mineralization:cornea | 0 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (4) | (0) | (0) | (0) | (6) | (0) | (0) | (0) | |
| Harder gl | hyperplasia | 0 | 0 | 0 | 0 | <50> | | | | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | | | | | (4) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| {Musculoskeletal system} | | | | | | | | | | | | | | | | | | | | | | |
| muscle | mineralization | 1 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| | | (2) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | |
| bone | osteosclerosis | 0 | 0 | 0 | 0 | <50> | | | | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | |
| | | (0) | (0) | (0) | (0) | | | | | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (0) | (2) | (0) | (0) | (0) | |
| Grade | 1 : Slight | 2 : Moderate | | | | 3 : Marked | | | | 4 : Severe | | | | | | | | | | | | |
| < a > | a : Number of animals examined at the site | | | | | | | | | | | | | | | | | | | | | |
| b | b : Number of animals with lesion | | | | | | | | | | | | | | | | | | | | | |
| (c) | c : b / a * 100 | | | | | | | | | | | | | | | | | | | | | |
| Significant difference : | | * : P ≤ 0.05 | | | | ** : P ≤ 0.01 | | | | Test of Chi Square | | | | | | | | | | | | |
| (HPT150) | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | |

BAIS4

TABLE O 1

NEOPLASTIC LESIONS-INCIDENCE AND
STATISTICAL ANALYSIS: MALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0580
ANIMAL : MOUSE B6D2F1/Cr-Lj[Crj:BDP1]
SEX : MALE

PAGE : 1

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|---|-------------|-------------|--------------|-------------|
| SITE : lung TUMOR : bronchiolar-alveolar adenoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 3/50(6.0) | 6/50(12.0) | 2/50(4.0) | 2/50(4.0) |
| Adjusted rates(b) | 9.09 | 13.04 | 5.56 | 5.00 |
| Terminal rates(c) | 3/33(9.1) | 4/34(11.8) | 2/36(5.6) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = ----- | | | |
| Prevalence method(d) | P = 0.8596 | | | |
| Combined analysis(d) | P = ----- | | | |
| Cochran-Armitage test(e) | P = 0.3226 | | | |
| Fisher Exact test(e) | | P = 0.2435 | P = 0.5000 | P = 0.5000 |
| SITE : lung TUMOR : bronchiolar-alveolar carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 6/50(12.0) | 4/50(8.0) | 8/50(16.0) | 7/50(14.0) |
| Adjusted rates(b) | 17.65 | 11.76 | 16.67 | 20.00 |
| Terminal rates(c) | 5/33(15.2) | 4/34(11.8) | 6/36(16.7) | 7/35(20.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.4556 | | | |
| Prevalence method(d) | P = 0.2959 | | | |
| Combined analysis(d) | P = 0.3046 | | | |
| Cochran-Armitage test(e) | P = 0.5395 | | | |
| Fisher Exact test(e) | | P = 0.3703 | P = 0.3871 | P = 0.5000 |
| SITE : lung TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 9/50(18.0) | 9/50(18.0) | 10/50(20.0) | 9/50(18.0) |
| Adjusted rates(b) | 26.47 | 20.59 | 22.22 | 22.86 |
| Terminal rates(c) | 8/33(24.2) | 7/34(20.6) | 8/36(22.2) | 8/35(22.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.4556 | | | |
| Prevalence method(d) | P = 0.5620 | | | |
| Combined analysis(d) | P = 0.5600 | | | |
| Cochran-Armitage test(e) | P = 0.9962 | | | |
| Fisher Exact test(e) | | P = 0.6024 | P = 0.5000 | P = 0.6024 |

(HPT360A)

BAIS4

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0580
ANIMAL : MOUSE B6D2F1/CrJ{CrJ:BDP1}
SEX : MALE

PAGE : 2

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|---|-------------|-------------|--------------|-------------|
| SITE : lung | | | | |
| TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma, squamous cell carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 9/50(18.0) | 9/50(18.0) | 11/50(22.0) | 9/50(18.0) |
| Adjusted rates(b) | 26.47 | 20.59 | 25.00 | 22.86 |
| Terminal rates(c) | 8/33(24.2) | 7/34(20.6) | 9/36(25.0) | 8/35(22.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.4556 | | | |
| Prevalence method(d) | P = 0.5610 | | | |
| Combined analysis(d) | P = 0.5591 | | | |
| Cochran-Armitage test(e) | P = 0.9924 | | | |
| Fisher Exact test(e) | | P = 0.6024 | P = 0.4016 | P = 0.6024 |
| SITE : lymph node | | | | |
| TUMOR : malignant lymphoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 3/50(6.0) | 6/50(12.0) | 8/50(16.0) | 2/50(4.0) |
| Adjusted rates(b) | 9.09 | 5.88 | 22.22 | 2.86 |
| Terminal rates(c) | 3/33(9.1) | 2/34(5.9) | 8/36(22.2) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.6351 | | | |
| Prevalence method(d) | P = 0.7743 | | | |
| Combined analysis(d) | P = 0.8057 | | | |
| Cochran-Armitage test(e) | P = 0.4275 | | | |
| Fisher Exact test(e) | | P = 0.2435 | P = 0.0999 | P = 0.5000 |
| SITE : spleen | | | | |
| TUMOR : hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 4/50(8.0) | 2/50(4.0) | 0/50(0.0) | 1/50(2.0) |
| Adjusted rates(b) | 8.89 | 0.0 | 0.0 | 0.0 |
| Terminal rates(c) | 1/33(3.0) | 0/34(0.0) | 0/36(0.0) | 0/35(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.4010 | | | |
| Prevalence method(d) | P = 0.9962 | | | |
| Combined analysis(d) | P = 0.9335 | | | |
| Cochran-Armitage test(e) | P = 0.1532 | | | |
| Fisher Exact test(e) | | P = 0.3389 | P = 0.0587 | P = 0.1811 |

(IPT360A)

BALS4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|--------------|--------------|--------------|--------------|
| SITE : spleen TUMOR : hemangioma, hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 4/50(8.0) | 3/50(6.0) | 2/50(4.0) | 1/50(2.0) |
| Adjusted rates(b) | 8.89 | 2.86 | 4.26 | 0.0 |
| Terminal rates(c) | 1/33(3.0) | 0/34(0.0) | 1/36(2.8) | 0/35(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.4010 | | | |
| Prevalence method(d) | P = 0.9755 | | | |
| Combined analysis(d) | P = 0.9246 | | | |
| Cochran-Armitage test(e) | P = 0.1665 | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.3389 | P = 0.1811 |
| SITE : stomach TUMOR : squamous cell papilloma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 0/50(0.0) | 4/50(8.0) | 3/50(6.0) | 6/50(12.0) |
| Adjusted rates(b) | 0.0 | 8.51 | 8.33 | 13.95 |
| Terminal rates(c) | 0/33(0.0) | 2/34(5.9) | 3/36(8.3) | 3/35(8.6) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.0273* | | | |
| Prevalence method(d) | P = 0.0273* | | | |
| Combined analysis(d) | P = 0.0365* | | | |
| Cochran-Armitage test(e) | P = 0.0365* | | | |
| Fisher Exact test(e) | | P = 0.0587 | P = 0.1212 | P = 0.0133* |
| SITE : liver TUMOR : hepatocellular adenoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 14/50(28.0) | 13/50(26.0) | 13/50(26.0) | 19/50(38.0) |
| Adjusted rates(b) | 33.33 | 31.43 | 33.33 | 42.86 |
| Terminal rates(c) | 11/33(33.3) | 10/34(29.4) | 12/36(33.3) | 15/35(42.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.2429 | | | |
| Prevalence method(d) | P = 0.1761 | | | |
| Combined analysis(d) | P = 0.1335 | | | |
| Cochran-Armitage test(e) | P = 0.1820 | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.5000 | P = 0.1976 |

(HPT360A)

BAIS4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|----------------------------------|--------------|--------------|--------------|--------------|
| SITE : liver | | | | |
| TUMOR : histiocytic sarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 0/50(0.0) | 3/50(6.0) | 0/50(0.0) | 2/50(4.0) |
| Adjusted rates(b) | 0.0 | 0.0 | 0.0 | 0.0 |
| Terminal rates(c) | 0/33(0.0) | 0/34(0.0) | 0/36(0.0) | 0/35(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.2791 | | | |
| Prevalence method(d) | P = | | | |
| Combined analysis(d) | P = 0.2791 | | | |
| Cochran-Armitage test(e) | P = 0.5274 | | | |
| Fisher Exact test(e) | | P = 0.1212 | P = N.C. | P = 0.2475 |
| SITE : liver | | | | |
| TUMOR : hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 5/50(10.0) | 3/50(6.0) | 0/50(0.0) | 1/50(2.0) |
| Adjusted rates(b) | 15.15 | 4.35 | 0.0 | 2.86 |
| Terminal rates(c) | 5/33(15.2) | 1/34(2.9) | 0/36(0.0) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5616 | | | |
| Prevalence method(d) | P = 0.9708 | | | |
| Combined analysis(d) | P = 0.9781 | | | |
| Cochran-Armitage test(e) | P = 0.0683 | | | |
| Fisher Exact test(e) | | P = 0.3575 | P = 0.0281* | P = 0.1022 |
| SITE : liver | | | | |
| TUMOR : hepatocellular carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 20/50(40.0) | 7/50(14.0) | 7/50(14.0) | 8/50(16.0) |
| Adjusted rates(b) | 42.42 | 18.92 | 11.11 | 15.38 |
| Terminal rates(c) | 14/33(42.4) | 6/34(17.6) | 4/36(11.1) | 5/35(14.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.8323 | | | |
| Prevalence method(d) | P = 0.9744 | | | |
| Combined analysis(d) | P = 0.9859 | | | |
| Cochran-Armitage test(e) | P = 0.0415* | | | |
| Fisher Exact test(e) | | P = 0.0031** | P = 0.0031** | P = 0.0067** |

(HPT360A)

DAIS4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|--------------|--------------|--------------|--------------|
| SITE : liver | | | | |
| TUMOR : hemangioma, hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 6/50(12.0) | 4/50(8.0) | 1/50(2.0) | 1/50(2.0) |
| Adjusted rates(b) | 16.67 | 6.52 | 2.70 | 2.86 |
| Terminal rates(c) | 5/33(15.2) | 2/34(5.9) | 0/36(0.0) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5616 | | | |
| Prevalence method(d) | P = 0.9855 | | | |
| Combined analysis(d) | P = 0.9890 | | | |
| Cochran-Armitage test(e) | P = 0.0385* | | | |
| Fisher Exact test(e) | | P = 0.3703 | P = 0.0559 | P = 0.0559 |
| SITE : liver | | | | |
| TUMOR : hepatocellular adenoma, hepatocellular carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 28/50(56.0) | 17/50(34.0) | 18/50(36.0) | 23/50(46.0) |
| Adjusted rates(b) | 58.82 | 41.67 | 38.89 | 48.57 |
| Terminal rates(c) | 19/33(57.6) | 13/34(38.2) | 14/36(38.9) | 17/35(48.6) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.6439 | | | |
| Prevalence method(d) | P = 0.6382 | | | |
| Combined analysis(d) | P = 0.6942 | | | |
| Cochran-Armitage test(e) | P = 0.8157 | | | |
| Fisher Exact test(e) | | P = 0.0219* | P = 0.0352* | P = 0.2119 |

(IPT360A)

BA1S4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|--------------|--------------|--------------|--------------|
| SITE : liver | | | | |
| TUMOR : hepatocellular adenoma, hepatocellular carcinoma, hepatoblastoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 29/50(58.0) | 18/50(36.0) | 18/50(36.0) | 24/50(48.0) |
| Adjusted rates(b) | 58.82 | 44.44 | 38.89 | 48.57 |
| Terminal rates(c) | 19/33(57.6) | 14/34(41.2) | 14/36(38.9) | 17/35(48.6) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5872 | | | |
| Prevalence method(d) | P = 0.6446 | | | |
| Combined analysis(d) | P = 0.6717 | | | |
| Cochran-Armitage test(e) | P = 0.8135 | | | |
| Fisher Exact test(e) | | P = 0.0223* | P = 0.0223* | P = 0.2115 |
| (IPT360A) | | | | |
| BAIS4 | | | | |

(a): Number of tumor-bearing animals/number of animals examined at the site.
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c): Observed tumor incidence at terminal kill.
 (d): Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$
 N.C.:Statistical value cannot be calculated and was not significant.

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|-----------------------------|------------|-------------|-------------|-------------|
| SITE : ALL SITE | | | | |
| TUMOR : histiocytic sarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 1/50(2.0) | 5/50(10.0) | 3/50(6.0) | 6/50(12.0) |
| Adjusted rates(b) | 0.0 | 2.94 | 5.56 | 8.57 |
| Terminal rates(c) | 0/33(0.0) | 1/34(2.9) | 2/36(5.6) | 3/35(8.6) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.3363 | | | |
| Prevalence method(d) | P = 0.0504 | | | |
| Combined analysis(d) | P = 0.0873 | | | |
| Cochran-Armitage test(e) | P = 0.1286 | | | |
| Fisher Exact test(e) | | P = 0.1022 | P = 0.3087 | P = 0.0559 |
| SITE : ALL SITE | | | | |
| TUMOR : malignant lymphoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 3/50(6.0) | 6/50(12.0) | 8/50(16.0) | 2/50(4.0) |
| Adjusted rates(b) | 9.09 | 5.88 | 22.22 | 2.86 |
| Terminal rates(c) | 3/33(9.1) | 2/34(5.9) | 8/36(22.2) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.6351 | | | |
| Prevalence method(d) | P = 0.7743 | | | |
| Combined analysis(d) | P = 0.8057 | | | |
| Cochran-Armitage test(e) | P = 0.4275 | | | |
| Fisher Exact test(e) | | P = 0.2435 | P = 0.0999 | P = 0.5000 |

STUDY No. : 0580
 ANIMAL : MOUSE B6D2F1/Cr-1J[Cr-j:BDFl]
 SEX : MALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 2

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--------------------------|-------------|------------|--------------|-------------|
| SITE : ALL SITE | | | | |
| TUMOR : hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 9/50(18.0) | 4/50(8.0) | 0/50(0.0) | 2/50(4.0) |
| Adjusted rates(b) | 20.00 | 2.94 | 0.0 | 2.86 |
| Terminal rates(c) | 6/33(18.2) | 1/34(2.9) | 0/36(0.0) | 1/35(2.9) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5266 | | | |
| Prevalence method(d) | P = 0.9984 | | | |
| Combined analysis(d) | P = 0.9930 | | | |
| Cochran-Armitage test(e) | P = 0.0233* | | | |
| Fisher Exact test(e) | | P = 0.1168 | P = 0.0013** | P = 0.0256* |

(IPT360A)

BAIS4

- (a): Number of tumor-bearing animals/number of animals examined at the site.
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c): Observed tumor incidence at terminal kill.
 (d): Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e): The Cochran Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible outcomes can not be estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$
 N.C.:Statistical value cannot be calculated and was not significant.

TABLE O 2

NEOPLASTIC LESIONS-INCIDENCE AND
STATISTICAL ANALYSIS: FEMALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

STUDY No. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[CrJ:BDP1]
SEX : FEMALE

PAGE : 7

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|---|--------------|--------------|-------------|-------------|
| SITE : lung TUMOR : bronchiolar-alveolar carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 2/50(4.0) | 1/50(2.0) | 2/50(4.0) | 4/50(8.0) |
| Adjusted rates(b) | 2.94 | 3.57 | 6.25 | 13.33 |
| Terminal rates(c) | 1/34(2.9) | 1/28(3.6) | 1/28(3.6) | 4/30(13.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 1.0000 ? | | | |
| Prevalence method(d) | P = 0.0359* | | | |
| Combined analysis(d) | P = 0.0842 | | | |
| Cochran-Armitage test(e) | P = 0.1929 | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.6913 | P = 0.3389 |
| SITE : lung TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 4/50(8.0) | 2/50(4.0) | 2/50(4.0) | 5/50(10.0) |
| Adjusted rates(b) | 8.82 | 4.00 | 6.25 | 16.67 |
| Terminal rates(c) | 3/34(8.8) | 1/28(3.6) | 1/28(3.6) | 5/30(16.7) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 1.0000 ? | | | |
| Prevalence method(d) | P = 0.1080 | | | |
| Combined analysis(d) | P = 0.1809 | | | |
| Cochran-Armitage test(e) | P = 0.4279 | | | |
| Fisher Exact test(e) | | P = 0.3389 | P = 0.3389 | P = 0.5000 |
| SITE : lymph node TUMOR : malignant lymphoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 12/50(24.0) | 16/50(32.0) | 7/50(14.0) | 7/50(14.0) |
| Adjusted rates(b) | 14.71 | 14.29 | 0.0 | 13.33 |
| Terminal rates(c) | 5/34(14.7) | 4/28(14.3) | 0/28(0.0) | 4/30(13.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.9462 | | | |
| Prevalence method(d) | P = 0.5803 | | | |
| Combined analysis(d) | P = 0.9286 | | | |
| Cochran-Armitage test(e) | P = 0.0662 | | | |
| Fisher Exact test(e) | | P = 0.2522 | P = 0.1540 | P = 0.1540 |

(IPT360A)

BAIS4

STUDY No. : 0580
ANIMAL : MOUSE B6D2F1/Cr1J(Crj:BDP1)
SEX : FEMALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 8

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|-------------|------------|------------|-------------|
| SITE : spleen TUMOR : hemangioma, hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 1/50(2.0) | 1/50(2.0) | 3/50(6.0) | 0/50(0.0) |
| Adjusted rates(b) | 2.94 | 3.23 | 7.32 | 0.0 |
| Terminal rates(c) | 1/34(2.9) | 0/28(0.0) | 2/28(7.1) | 0/30(0.0) |
| Statistical analysis | | | | |
| Peto test | P = ----- | | | |
| Standard method(d) | P = 0.6950 | | | |
| Prevalence method(d) | P = ----- | | | |
| Combined analysis(d) | P = 0.4818 | | | |
| Cochran-Armitage test(e) | | P = 0.7525 | P = 0.3087 | P = 0.5000 |
| Fisher Exact test(e) | | | | |
| SITE : stomach TUMOR : squamous cell papilloma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 0/50(0.0) | 1/50(2.0) | 1/50(2.0) | 3/50(6.0) |
| Adjusted rates(b) | 0.0 | 2.70 | 2.63 | 9.09 |
| Terminal rates(c) | 0/34(0.0) | 0/28(0.0) | 0/28(0.0) | 2/30(6.7) |
| Statistical analysis | | | | |
| Peto test | P = ----- | | | |
| Standard method(d) | P = 0.0279* | | | |
| Prevalence method(d) | P = ----- | | | |
| Combined analysis(d) | P = 0.0549 | | | |
| Cochran-Armitage test(e) | | P = 0.5000 | P = 0.5000 | P = 0.1212 |
| Fisher Exact test(e) | | | | |
| SITE : liver TUMOR : hemangioma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 2/50(4.0) | 1/50(2.0) | 2/50(4.0) | 4/50(8.0) |
| Adjusted rates(b) | 5.88 | 3.57 | 5.13 | 13.33 |
| Terminal rates(c) | 2/34(5.9) | 1/28(3.6) | 1/28(3.6) | 4/30(13.3) |
| Statistical analysis | | | | |
| Peto test | P = ----- | | | |
| Standard method(d) | P = 0.0872 | | | |
| Prevalence method(d) | P = ----- | | | |
| Combined analysis(d) | P = 0.1929 | | | |
| Cochran-Armitage test(e) | | P = 0.5000 | P = 0.6913 | P = 0.3389 |
| Fisher Exact test(e) | | | | |

(IPT360A)

BAIS-4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|-------------|-------------|-------------|-------------|
| SITE : liver TUMOR : hepatocellular adenoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 5/50(10.0) | 6/50(12.0) | 4/50(8.0) | 3/50(6.0) |
| Adjusted rates(b) | 14.71 | 21.43 | 11.11 | 10.00 |
| Terminal rates(c) | 5/34(14.7) | 6/28(21.4) | 3/28(10.7) | 3/30(10.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = ----- | | | |
| Prevalence method(d) | P = 0.7948 | | | |
| Combined analysis(d) | P = ----- | | | |
| Cochran-Armitage test(e) | P = 0.3423 | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.5000 | P = 0.3575 |
| SITE : liver TUMOR : hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 4/50(8.0) | 3/50(6.0) | 0/50(0.0) | 0/50(0.0) |
| Adjusted rates(b) | 11.76 | 6.45 | 0.0 | 0.0 |
| Terminal rates(c) | 4/34(11.8) | 1/28(3.6) | 0/28(0.0) | 0/30(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5483 | | | |
| Prevalence method(d) | P = 0.9945 | | | |
| Combined analysis(d) | P = 0.9950 | | | |
| Cochran-Armitage test(e) | P = 0.0227* | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.0587 | P = 0.0587 |
| SITE : liver TUMOR : hepatocellular carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 0/50(0.0) | 3/50(6.0) | 1/50(2.0) | 1/50(2.0) |
| Adjusted rates(b) | 0.0 | 9.68 | 3.13 | 2.94 |
| Terminal rates(c) | 0/34(0.0) | 2/28(7.1) | 0/28(0.0) | 0/30(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = ----- | | | |
| Prevalence method(d) | P = 0.4950 | | | |
| Combined analysis(d) | P = ----- | | | |
| Cochran-Armitage test(e) | P = 0.9335 | | | |
| Fisher Exact test(e) | | P = 0.1212 | P = 0.5000 | P = 0.5000 |

(IIP1350A)

BAIS4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|-------------|-------------|-------------|-------------|
| SITE : liver TUMOR : hemangioma, hemangiosarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 6/50(12.0) | 4/50(8.0) | 2/50(4.0) | 4/50(8.0) |
| Adjusted rates(b) | 17.65 | 9.68 | 5.13 | 13.33 |
| Terminal rates(c) | 6/34(17.6) | 2/28(7.1) | 1/28(3.6) | 4/30(13.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5483 | | | |
| Prevalence method(d) | P = 0.5917 | | | |
| Combined analysis(d) | P = 0.6467 | | | |
| Cochran-Armitage test(e) | P = 0.5831 | | | |
| Fisher Exact test(e) | | P = 0.3703 | P = 0.1343 | P = 0.3703 |
| SITE : liver TUMOR : hepatocellular adenoma, hepatocellular carcinoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 5/50(10.0) | 8/50(16.0) | 5/50(10.0) | 4/50(8.0) |
| Adjusted rates(b) | 14.71 | 25.81 | 13.89 | 11.76 |
| Terminal rates(c) | 5/34(14.7) | 7/28(25.0) | 3/28(10.7) | 3/30(10.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.7368 | | | |
| Prevalence method(d) | P = 0.7368 | | | |
| Combined analysis(d) | P = 0.4393 | | | |
| Cochran-Armitage test(e) | | P = 0.2768 | P = 0.6297 | P = 0.5000 |
| Fisher Exact test(e) | | | | |
| SITE : pituitary gland TUMOR : adenoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 2/50(4.0) | 7/50(14.0) | 5/50(10.0) | 6/50(12.0) |
| Adjusted rates(b) | 0.0 | 17.86 | 12.50 | 20.00 |
| Terminal rates(c) | 0/34(0.0) | 5/28(17.9) | 3/28(10.7) | 6/30(20.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.9012 | | | |
| Prevalence method(d) | P = 0.0427* | | | |
| Combined analysis(d) | P = 0.1642 | | | |
| Cochran-Armitage test(e) | P = 0.4128 | | | |
| Fisher Exact test(e) | | P = 0.0798 | P = 0.2180 | P = 0.1343 |

(HPT360A)

BAIS4

STUDY No. : 0580
ANIMAL : MOUSE B6D2F1/Gr-1j[Crj:BDP1]
SEX : FEMALE

NEOPLASTIC LESIONS—INCIDENCE AND STATISTICAL ANALYSIS

PAGE : 11

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--|--------------|-------------|--------------|--------------|
| SITE : uterus TUMOR : histiocytic sarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 12/50(24.0) | 7/50(14.0) | 12/50(24.0) | 13/50(26.0) |
| Adjusted rates(b) | 17.65 | 7.14 | 7.14 | 10.00 |
| Terminal rates(c) | 6/34(17.6) | 2/28(7.1) | 2/28(7.1) | 3/30(10.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.0484* | | | |
| Prevalence method(d) | P = 0.7898 | | | |
| Combined analysis(d) | P = 0.1667 | | | |
| Cochran-Armitage test(e) | P = 0.4290 | | | |
| Fisher Exact test(e) | | P = 0.1540 | P = 0.5924 | P = 0.5000 |
| SITE : Harderian gland TUMOR : adenoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 0/50(0.0) | 1/50(2.0) | 4/50(8.0) | 2/50(4.0) |
| Adjusted rates(b) | 0.0 | 3.57 | 9.30 | 5.71 |
| Terminal rates(c) | 0/34(0.0) | 1/28(3.6) | 2/28(7.1) | 1/30(3.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = ----- | | | |
| Prevalence method(d) | P = 0.1228 | | | |
| Combined analysis(d) | P = ----- | | | |
| Cochran-Armitage test(e) | P = 0.2968 | | | |
| Fisher Exact test(e) | | P = 0.5000 | P = 0.0587 | P = 0.2475 |

(IPT360A)

BALS4

- (a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not be estimated or this P-value is beyond the estimated P-value.
----- : There is no data which should be statistical analysis.
Significant difference : * : $P \leq 0.05$ ** : $P \leq 0.01$
N.C.:Statistical value cannot be calculated and was not significant.

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|-----------------------------|--------------|--------------|--------------|--------------|
| SITE : ALL SITE | | | | |
| TUMOR : histiocytic sarcoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 14/50(28.0) | 9/50(18.0) | 12/50(24.0) | 17/50(34.0) |
| Adjusted rates(b) | 20.59 | 14.29 | 7.14 | 10.00 |
| Terminal rates(c) | 7/34(20.6) | 4/28(14.3) | 2/28(7.1) | 3/30(10.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.0076** | | | |
| Prevalence method(d) | P = 0.9033 | | | |
| Combined analysis(d) | P = 0.0837 | | | |
| Cochran-Armitage test(e) | P = 0.2091 | | | |
| Fisher Exact test(e) | | P = 0.1710 | P = 0.4100 | P = 0.3329 |
| SITE : ALL SITE | | | | |
| TUMOR : malignant lymphoma | | | | |
| Tumor rate | | | | |
| Overall rates(a) | 12/50(24.0) | 16/50(32.0) | 7/50(14.0) | 7/50(14.0) |
| Adjusted rates(b) | 14.71 | 14.29 | 0.0 | 13.33 |
| Terminal rates(c) | 5/34(14.7) | 4/28(14.3) | 0/28(0.0) | 4/30(13.3) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.9462 | | | |
| Prevalence method(d) | P = 0.5803 | | | |
| Combined analysis(d) | P = 0.9286 | | | |
| Cochran-Armitage test(e) | P = 0.0662 | | | |
| Fisher Exact test(e) | | P = 0.2522 | P = 0.1540 | P = 0.1540 |

(IPT360A)

BAIS4

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|--------------------------|-------------------------|------------|------------|-------------|
| | SITE : ALL SITE | | | |
| | TUMOR : hemangiosarcoma | | | |
| Tumor rate | | | | |
| Overall rates(a) | 5/50(10.0) | 3/50(6.0) | 1/50(2.0) | 0/50(0.0) |
| Adjusted rates(b) | 14.71 | 6.45 | 2.44 | 0.0 |
| Terminal rates(c) | 5/34(14.7) | 1/28(3.6) | 0/28(0.0) | 0/30(0.0) |
| Statistical analysis | | | | |
| Peto test | | | | |
| Standard method(d) | P = 0.5483 | | | |
| Prevalence method(d) | P = 0.9934 | | | |
| Combined analysis(d) | P = 0.9945 | | | |
| Cochran-Armitage test(e) | P = 0.0182* | | | |
| Fisher Exact test(e) | | P = 0.3575 | P = 0.1022 | P = 0.0281* |

(HPT360A)

BAIS4

(a): Number of tumor-bearing animals/number of animals examined at the site.
 (b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
 (c): Observed tumor incidence at terminal kill.
 (d): Beneath the control incidence are the P-values associated with the trend test.
 Standard method : Death analysis
 Prevalence method : Incidental tumor test
 Combined analysis : Death analysis + Incidental tumor test
 (e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
 ? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
 ----- : There is no data which should be statistical analysis.
 Significant difference : * : P ≤ 0.05 ** : P ≤ 0.01
 N.C.:Statistical value cannot be calculated and was not significant.

TABLE Q 1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER:

B6D2F1/Crlj MALE MICE

TABLE Q1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN
JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj MALE MICE

| Organs Tumors | No. of animals examined | No. of animals bearing tumor | Incidence (%) | Min. - Max. (%) |
|------------------------------------|----------------------------|---------------------------------|------------------|--------------------|
| Stomach Squamous cell papilloma | 1946 | 5 | 0.3 | 0 - 2 |

39 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0044, 0060, 0062, 0064, 0066, 0068, 0096, 0105, 0116, 0140, 0159, 0163, 0190, 0206,
0211, 0225, 0243, 0268, 0270, 0279, 0285, 0297, 0319, 0329, 0343, 0348, 0366, 0372,
0402, 0406, 0418, 0422, 0438, 0449, 0458, 0462, 0498, 0515, 0561

TABLE Q 2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC
LESIONS IN JAPAN BIOASSAY RESEARCH CENTER:

B6D2F1/Crlj FEMALE MICE

TABLE Q2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj FEMALE MICE

| Organs Tumors | No. of animals examined | No. of animals bearing tumor | Incidence (%) | Min. - Max. (%) | |
|--|----------------------------|---------------------------------|------------------|--------------------|---|
| Stomach Squamous cell papilloma | 1947 | 8 | 0.4 | 0 - 6 | ✓ |
| Lung Bronchiolar-alveolar carcinoma | 1947 | 55 | 2.8 | 0 - 8 | ✓ |
| Pituitary gland Adenoma | 1938 | 277 | 14.3 | 2 - 34 | ✓ |
| Uterus Histiocytic sarcoma | 1947 | 401 | 20.6 | 10 - 32 | ✓ |
| All organ Histiocytic sarcoma | 1947 | 456 | 23.4 | 12 - 36 | ✓ |

39 carcinogenicity studies examined in Japan Bioassay Research Center were used.

Study No. : 0044, 0060, 0062, 0064, 0066, 0068, 0096, 0105, 0116, 0140, 0159, 0163, 0190, 0206, 0211, 0225, 0243, 0268, 0270, 0279, 0285, 0297, 0319, 0329, 0343, 0348, 0366, 0372, 0402, 0406, 0418, 0422, 0438, 0449, 0458, 0462, 0498, 0515, 0561

TABLE R

CAUSE OF DEATH OF MICE IN THE 2-YEAR FEED STUDY OF
2-AMINO-4-CHLOROPHENOL

STUDY NO. : 0580
 ANIMAL : MOUSE B6D2F1/CrJ[Crj:DOF1]
 SEX : MALE

COUSE OF DEATH (SUMMARY)
 (0-105W)

PAGE : 1

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|------------------------------------|---------|---------|----------|----------|
| Number of Dead and Moribund Animal | 17 | 16 | 14 | 15 |
| no microscop confirm | 0 | 0 | 1 | 2 |
| digestive sy les | 0 | 1 | 0 | 0 |
| urinary retention | 4 | 1 | 4 | 2 |
| arthritis | 1 | 0 | 0 | 0 |
| tooth lesion | 0 | 0 | 1 | 0 |
| hydronephrosis | 2 | 0 | 0 | 1 |
| peritonitis | 0 | 0 | 1 | 0 |
| tumor d:leukemia | 0 | 4 | 0 | 1 |
| tumor d:subcutis | 1 | 1 | 1 | 0 |
| tumor d:lung | 0 | 0 | 2 | 0 |
| tumor d:lymph node | 1 | 0 | 0 | 0 |
| tumor d:spleen | 0 | 2 | 0 | 1 |
| tumor d:liver | 8 | 5 | 3 | 7 |
| tumor d:epididymis | 0 | 0 | 1 | 0 |
| tumor d:peripl nerv | 0 | 1 | 0 | 1 |
| tumor d:harder gl | 0 | 1 | 0 | 0 |

(H10120)

BA154

STUDY NO. : 0580
ANIMAL : MOUSE B6D2F1/CrJ[Crj:BDP1]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0-105W)

PAGE : 2

| Group Name | Control | 512 ppm | 1280 ppm | 3200 ppm |
|------------------------------------|---------|---------|----------|----------|
| Number of Dead and Moribund Animal | 16 | 22 | 22 | 20 |
| no microscop confirm | 0 | 0 | 1 | 0 |
| cardiovascular les | 0 | 0 | 0 | 1 |
| renal lesion | 0 | 0 | 1 | 0 |
| thrombosis | 0 | 0 | 0 | 1 |
| tooth lesion | 0 | 1 | 0 | 0 |
| hydronephrosis | 0 | 0 | 1 | 0 |
| tumor d:leukemia | 7 | 12 | 7 | 3 |
| tumor d:lung | 1 | 0 | 0 | 0 |
| tumor d:spleen | 1 | 0 | 0 | 2 |
| tumor d:liver | 0 | 1 | 0 | 2 |
| tumor d:pituitary | 2 | 1 | 1 | 0 |
| tumor d:ovary | 0 | 1 | 0 | 1 |
| tumor d:uterus | 5 | 5 | 11 | 10 |
| tumor d:bone | 0 | 1 | 0 | 0 |

(B10120)

BAIS4

FIGURES

- FIGURE 1 SURVIVAL ANIMAL RATE OF MALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL
- FIGURE 2 SURVIVAL ANIMAL RATE OF FEMALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL
- FIGURE 3 BODY WEIGHT CHANGES OF MALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL
- FIGURE 4 BODY WEIGHT CHANGES OF FEMALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL
- FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL
- FIGURE 6 FOOD CONSUMPTION CHANGES OF FEMALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 1 SURVIVAL ANIMAL RATE OF MALE MICE IN THE 2-YEAR
FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 2 SURVIVAL ANIMAL RATE OF FEMALE MICE IN THE 2-YEAR
FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 3 BODY WEIGHT CHANGES OF MALE MICE IN THE 2-YEAR
FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 4 BODY WEIGHT CHANGES OF FEMALE MICE IN THE 2-YEAR
FEED STUDY OF 2-AMINO-4-CHLOROPHENOL




FIGURE 5 FOOD CONSUMPTION CHANGES OF MALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL





FIGURE 6 FOOD CONSUMPTION CHANGES OF FEMALE MICE IN THE 2-YEAR FEED STUDY OF 2-AMINO-4-CHLOROPHENOL



Photograph 1

Forestomach: Squamous cell papilloma

Mouse, Male, 1280 ppm, Animal No. 0580-1236 (H&E)